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ABSTRACT OF DISSERTATION 
 
 
EXPLORING THE EFFECT OF CHRONIC INFLAMMATION ON RESPONSE 
TO IMMUNE CHECKPOINT INHIBITORS IN CANCER 
 
Precision medicine has allowed for the development of monoclonal antibodies that 
unmask the anti-tumor immune response. These agents have provided some patients 
durable clinical benefit. However, PD-1 and PD-L1 inhibitor therapies are effective in a 
small group (10-20%) of non-small cell lung cancer (NSCLC) patients when used as 
single-agent therapy. The approved companion diagnostic is expression of the immune 
cell surface molecule, programmed death ligand 1 (PD-L1), on tumors measured by 
immunohistochemistry (IHC). Studies in tumor biology and immune surveillance dictate 
that PD-1 inhibitor efficacy should depend on the level of PD-L1 expression; however, 
the literature has not followed with convincing evidence. The limitations of this test 
include timing of tissue acquisition, tumor heterogeneity, and timing of therapy relative to 
the expression of PD-L1. In addition, the requirement of analyzing tumor tissue biopsy 
samples from a patient is cumbersome. Thus, a peripheral blood biomarker that predicts 
efficacy of PD-1/PD-L1 inhibition would be optimal for precise and cost-effective 
treatment. A history of chronic inflammatory diseases may be advantageous for a cancer 
patient who is treated with PD-1/PD-L1 inhibitors and may allow them to then mobilize a 
swift immune response to tumor cells. Specific biological components of this persistent 
inflammation may predict PD-1 inhibitor response. We have taken a novel approach to 
leverage national healthcare claims data that couples patient history with response to 
therapy. We have identified potential peripheral blood biomarkers of response to PD-
1/PD-L1 inhibitors using a combination of healthcare outcomes and molecular markers 
that correlate with therapeutic efficacy. 
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CHAPTER 1  
A. CANCER & THE IMMUNE RESPONSE OVERVIEW 
Cancer Overview 
Cancer is understood to be a disease of unchecked cell growth due to genetic mutation; 
a continuous series of genetic events that guide cells to uncontrolled proliferation and 
invasion into surrounding tissue. Tumor cells gain the ability to survive independently 
and metastasize to other organs within the body (1).  Multiple organ involvement and 
ultimate failure is the final state of late-stage disease, resulting in death. Standard of 
care for cancer includes the resection of the malignant tissue, radiotherapy, and 
systemic chemotherapy.  Resection of the malignancy, the only treatment which can be 
considered a cure among solid tumors, is typically only possible when the disease is 
localized and detected early (2).  Unfortunately, patients with aggressive cancer types, 
including lung cancer, are diagnosed during late stage disease resulting in high mortality 
rates (3). Hanahan and Weinberg published the first iteration of The Hallmarks of Cancer 
in the year 2000 wherein they described six major factors influencing cancer biology; 
self-sufficiency in growth signals, insensitivity to anti-growth signals, evading apoptosis, 
limitless replicative potential, sustained angiogenesis, and tissue invasion and 
metastasis (1). Specifically, normal cells require mitogens to signal them to undergo 
growth and division; however, cancer cells are often able to grow despite the lack of 
external signals. Tumor suppressor genes are expressed to halt division in normal cells; 
however, cancer cells harbor mutated tumor suppressor genes resulting in aberrant 
progression through the cell cycle. Apoptosis is the programmed self-destruct function of 
nucleated cells to prevent the formation of abnormalities such as aberrant growth. 
Cancer cells can evade this programming. Normal cells have a finite number of divisions 
before a cell becomes unable to divide, known as senescence. Cancer cells overcome 
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this limit by disabling the pRB, p53 tumor suppressor proteins and maintaining 
telomeres. Angiogenesis is the generation of new blood vessels from pre-existing 
vessels and is essential for the transportation of oxygen. New blood vessels are typically 
generated during wound repair and the development of embryos; however, cancer cells 
can trigger the production of new vasculature. Lastly, cancer cells can undergo 
transformation from an epithelial form to mesenchymal form to break away from the 
primary tumor site to metastasize to distant organs. In 2011, Hanahan and Weinberg 
supported the inclusion of four additional hallmarks; reprogramming of energy 
metabolism, genome instability, inflammation and evading the immune response (4). 
Specifically, cancer cells prevent mitochondria from normal aerobic respiration leading to 
the decreased production of ATP. The resulting low ATP: ADP ratio deactivates 
mitochondria and prevents triggering of apoptosis. Cancer cells can harbor 
chromosomal abnormalities such as tetraploidy or trisomy making DNA more susceptible 
to mutations. Local chronic inflammation can, over time, cause DNA damage leading to 
the development of cancer cells. The discovery that cancer cells use mechanisms to 
evade the immune response initiated investigations into medications that would retarget 
the immune response to cancer. 
 
Cancer immunosurveillance describes a mechanism by which tumor cells are 
recognized and subsequently destroyed by the immune system (5, 6). Exploitation of 
immune mechanisms and evasion of immune surveillance are activities that survived 
selection in cells that underwent random mutagenesis to ensure the rise of a tumor. 
Tumor-associated antigens (TAAs) as well as neoantigens released by the cancer cells 
enter the blood circulation and initiate the triggering of the immune response (Figure 
1.1). The tumor microenvironment contains multiple immune cell-types, including 
macrophages, dendritic cells, natural killer (NK) cells, mast cells, B cells, and T cells 
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including T helper 1 (Th1) CD4+, T helper 2 (Th2) CD4+, regulatory T cells (TReg) and 
cytotoxic CD8+ T cells (7). The presence of the immune cells as well as cytokines and 
chemokines in the tumor microenvironment aid the growth and viability of the cancer 
cell. The immune response is differentiated into two types: the innate immune response 
and the adaptive immune response. The immune cells that are part of the innate 
response include dendritic cells, macrophages, NK cells and mast cells that are the first 
to respond to foreign agents. These cells, however, are not specially targeted for the 
cancer cells. The adaptive response typically follows the innate response. Its potency 
and effectiveness is greater than the innate response due to the priming and activation 
of these cells for the specific target. Certain adaptive immune cells can exert anti-tumor 
effects by recognizing TAAs or neoantigens presented on major histocompatibility 
complex (MHC) molecules (Figure 1.1). These antigens are presented to T cells via 
MHC class I or MHC class II on antigen presenting cells (APC) within lymph nodes. The 
presentation of the antigen requires additional co-stimulatory signals to induce T cell 
activation and expansion. Binding of B7 (CD80/CD86) on the APC to CD28 on the T cell 
leads to proliferation and differentiation via production of cytokines including interleukin 
(IL)-2. The effect is to drive clonal expansion of the activated T cell and to recruit other 
immune effector cells. Th1 and Th2 T cells secrete cytokines and chemokines that help 
to regulate this process with Th1 T cells activating CD8+ T cells and Th2 cells activating 
B cells. The primed T cells then exit the lymph node and are trafficked to the tumor site 
infiltrating the tumor. The cancer cells can then be destroyed by direct cell-mediated 
cytotoxicity. This adaptive immune response limits the establishment of cancer. 
However, in some cases tumor cells can escape the selective pressure from the immune 
system that allow tumor progression in the face of an ongoing immune response (8, 9).  
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Figure 1.1: Normal adaptive immune response to tumor associated antigens (TAAs). 
Used with permission from Macmillan Publishers Ltd: Nature Reviews Cancer, 6, 24-37, 
copyright 2006. 
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Selection of tumor cells with the ability to increase the expression of certain markers that 
alter natural immune defenses of the host is favored, protecting themselves from 
destruction. Specifically, many tumors acquire the ability to modify cell surface epitopes 
and upregulate immune checkpoint molecules such as cytotoxic T-lymphocyte-
associated protein 4 (CTLA-4), programmed death-ligand 1 (PD-L1), lymphocyte 
activation gene 3 protein (LAG-3), and T cell immunoglobulin domain and mucin domain-
containing protein 3 (TIM-3), thereby resisting an immune response (9-11). Programmed 
death cell protein 1 (PD-1), is normally expressed on CD4+ or CD8+ T cells. Antigen 
presenting cells (APC) normally express PD-L1 that, when bound by PD-1 on T cells, 
signal an exhausted active immune response. Evaluation of T cells in the tumor 
microenvironment show that these cells are often in the exhausted state leading to 
cancer immune evasion (Figure 1.2) (12). A growing approach to cancer therapy is the 
development of agents that block these immunosuppressive mechanisms by interfering 
with these checkpoint sites. 
Immune Response Deregulation 
Naïve T cells undergo maturity in response to acute events such as bacterial/viral 
infections or vaccinations over a 1-2 week period resulting in differentiation into T cells 
with effector functions (13, 14). Following clonal expansion and the clearance of the 
foreign antigen, a subset of T cells remain and become memory T cells. This pool of 
memory T cells retains the ability to rapidly reactivate effector functions against any 
future recurrence of the stimulating antigen. However, these functional, persistent 
memory T cells mature in the absence of continual antigen stimulation and after 
inflammation from the effector phase has subsided. 
 
In stark contrast, chronic conditions, such as cancer, involve persistent antigen exposure 
and chronic inflammation which then alters the development of memory T cells (15-17). 
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The alteration of these memory T cells, known as T cell exhaustion, includes key 
characteristics such as sustained upregulation and co-expression of multiple inhibitory 
receptors. Another characteristic of T cell exhaustion is the loss of secreted cytokine 
including interleukin-2 (IL-2), interferon gamma (IFN-γ) and tumor necrosis factor alpha 
(TNFα) (18, 19). T cells in this hypo-responsive state have been described in multiple 
conditions, including chronic viral infections such as lymphocytic choriomeningitis virus 
(LCMV), HIV and hepatitis C virus, in addition to cancer (20). Overexpression of 
inhibitory receptors PD-1 and CTLA-4, can be reversed to allow the immune response 
against these conditions (20, 21). The molecular mechanisms by which inhibitory 
receptors regulate T cell exhaustion remain unknown; however, there are several 
mechanisms discussed in the literature. First, inhibitory receptors may block target 
receptors or ligands preventing the formation of lipid rafts, as has been shown with 
CTLA-4 (22). Second, modulation of intracellular mediators downstream of receptor 
signaling can lessen the influence of activating signals from receptors such as TCR and 
co-stimulatory receptors (23). Lastly, induction of inhibitory genes such as basic leucine 
transcription factor, ATF-like (BATF) may lead to T cell exhaustion (24).  
 
There are several cell surface interactions that mediate T cell exhaustion (Figure 1.2). 
Upon T cell activation due to an acute event, PD-1 expression is upregulated; however, 
during chronic infections, co-expression of other cell surface inhibitory molecules such 
LAG-3, CD160, TIM-3 and CTLA-4 has been observed [(25, 26). LAG-3 is a cell surface 
protein that is structurally homologous to CD4 and binds to MHCII, inhibiting CD4-
dependent downstream signaling (27). Immune checkpoints, consisting of stimulatory or 
inhibitory signals, regulate T cell activation and effector functions to sustain self-
tolerance and minimize normal tissue damage (28). Blockade of more than one immune 
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checkpoint, such as PD-1 and LAG-3, results in improved reversal of T cell exhaustion 
(25, 29, 30).  
 
In addition to the immune checkpoint receptors and proteins expressed on immune cell 
components, certain soluble factors found in the tumor microenvironment and periphery 
that also play a role in the induction and suppression of the exhausted T cells. 
Overexpression of inflammatory or immunosuppressive cytokines that induce T cell 
exhaustion are important soluble factors. Chronic interferon alpha and interferon beta 
(IFN-α/β) signaling has been shown to induce T cell exhaustion during chronic infection 
(31). IL-10 blockade has been shown to restore T cell function during chronic viral 
infections (32). Certain cytokines, such as IL-6 and IL-27, induce the exhausted T cell 
phenotype (33, 34). In addition, blockade of PD-1 and IL-10 simultaneously in mice 
synergistically reverses CD8+ T cell exhaustion (35). Lastly, in vivo inhibition of 
transforming growth factor-β (TGF-β) signaling in CD8+ T cells improved the function of 
exhausted T cells (36). Despite the present evidence that certain cytokines have direct 
or indirect influence on T cell exhaustion, the precise mechanism has not been defined. 
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Figure 1.2: Mechanisms of tumor immune evasion. Used with permission from 
Macmillan Publishers Ltd: Nature Reviews Cancer, 12, 252-264, copyright 2012. 
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B. CANCER IMMUNOTHERAPY 
 
Immunotherapy describes several modes of treatment that aim to reorient the immune 
system to fight cancer. Early on, IL-2, an inducer of T cell expansion, was the first 
introduced in the treatment of cancer (37). IL-2 treatment is capable of mediating tumor 
regression in tumors; however, the toxicity profile manifests in multiple organ systems 
presenting as severe flu-like symptoms. Most common of these is capillary leak 
syndrome, a hypovolemic state and fluid accumulation the extravascular space leading 
to oliguria and ischemia. The toxicity profile of this treatment limited its clinical use. 
Another form of immunotherapy called adoptive cell transfer (ACT) was recently 
developed to utilize the patient’s own T cells with anti-tumor activity and expand those 
cells in vitro then reinfusing into the patient (38). Once reinfused, the T cells require 
binding to MHC molecules to induce their functions; however, tumor intrinsic functions 
may downregulate MHC on the surface of the tumor cell. Next, Chimeric antigen 
receptors (CAR) T cells were developed as engineered, patient-derived T cells with the 
ability to recognize and kill tumor cells without the MHC binding requirement (39). CAR T 
cells have additional co-stimulatory molecules that enhance its ability to proliferate. For 
example, a patient with advanced follicular lymphoma treated with CAR T-cell therapy 
targeting CD19 presented with dramatic regression after infusion (40). Finally, immune 
checkpoint inhibition (ICI) is a new mode of immunotherapy that has truly revolutionized 
cancer treatment and exhibits impressive responses in several tumor. The focus of my 
research explored markers of the immune response that may be associated with 
improved response to ICIs. 
 
Inhibition of immune checkpoints has multiple FDA-approved indications for the 
treatment of various malignancies, including melanoma, non-small cell lung cancer 
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(NSCLC), bladder cancer and many more, and has allowed clinicians another tool in 
their armament of cancer treatments (41-44). This form of treatment shifts the 
perspective from giving a patient medication to destroy tumor cells to giving medication 
to aid their immune system in mounting a response against the tumor. The medications 
include agents that target immune checkpoints such as ipilimumab (Yervoy®, Bristol-
Myers Squibb), an antibody to CTLA-4, nivolumab (Opdivo®, Bristol-Myers Squibb), and 
pembrolizumab (Keytruda®, Merck) which are antibodies to programmed cell death 
protein 1 (PD-1), the receptor for PD-L1, as well as atezolizumab (Tecentriq®, 
Genentech), avelumab (Bavencia®, Merck/Pfizer), and durvalumab (Imfinzi®, 
AstraZeneca), antibodies to PD-L1. The checkpoints these medications target act as 
mediators for the balance and escape phases of cancer immune editing, as discussed 
above. By targeting these inhibitory receptors, cancer cells lose the ability to suppress 
the antitumor response. 
 
The use of ICIs in oncology has been met with excitement and hope as another pillar of 
treatment that is promising and results in long and durable responses. In the treatment 
of NSCLC patients, Nivolumab improved median overall survival as compared to 
Docetaxel treatment (9.2 mos vs. 6.0 mos; P <0.001) (42). Dual blockade of PD-1 and 
CTLA-4 in patients with melanoma has demonstrated improved tumor control with 
median duration of response at 22.3 months (45, 46).  In addition to the improvement of 
overall survival, the treatment regimen is more tolerable as compared with docetaxel 
with less grade 3/4 adverse events. Importantly, in a long-term follow-up study of 129 
nivolumab-treated patients with NSCLC, the 3-year OS rate was only 18% (47). The 
benefit of ICIs is the potential for long, durable responses, however, it’s been shown that 
approximately 20% of the treated-population actually realizes benefit (48, 49). To 
improve that response, durable biomarkers of response are essential for clinical 
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management. Herein I review the body of scientific work assessing both tumor-specific 
and peripheral blood markers that are promising predictive biomarkers (Table 1). 
 
C. TUMOR BIOMARKERS OF RESPONSE 
 
Due to a low percentage of durable responders to ICI treatment, research efforts into 
developing predictive biomarkers of response began (Table 1.1). Given the mechanism 
of action of PD-1 and PD-L1 inhibitors, initial studies into biomarkers tried to determine 
whether the efficacy of these monoclonal antibodies correlated with PD-L1 expression in 
the tumor. 
PD-L1 Expression  
PD-L1 is a ligand of the PD-1 receptor, expressed on both tumor cells and APCs, and 
plays an important role in the inhibition of the normal T cell-mediated immune response. 
When PD-L1, expressed on the tumor cell, binds to PD-1 receptor on T cells, this leads 
to exhaustion of effector T cells and poorer prognosis of the patient (50). For the agents 
targeting the PD-1/PD-L1 axis, tumor expression of PD-L1 has been used as a method 
of selecting appropriate patients to be treated; however, it has not proven to be universal 
(51, 52). In cancers that express PD-L1, the interaction with the PD-1 receptor 
expressed on T cells, B cells, and natural killer (NK) cells of an activated immune system 
characterize an immune-evasive response by the tumor. Monoclonal antibodies that 
then bind to PD-1 or PD-L1 prevent cancer cells’ immune evasion (53). For this reason, 
expression of PD-L1 is currently utilized in the clinic as the best available biomarker to 
predict response to ICI targeting this checkpoint (51, 53, 54).  
 
Interpretation of PD-L1 expression levels has caused confusion as there are several 
methodologies that utilize different cut-offs differentiating between positive and negative 
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expression. The currently utilized companion diagnostic tools were developed for use 
with pembrolizumab and nivolumab, both PD-1 inhibitors. Each measurement is 
completed using immunohistochemistry (IHC). However, there were two antibodies 
developed specifically for each of the medications; antibody 22C3, anti-PD-L1, for 
pembrolizumab and antibody 28-8, anti-PD-L1, for nivolumab. The Tumor Proportion 
Score (TPS) is the percentage of PD-L1 positive tumor cells showing partial or complete 
membrane staining relative to all viable tumor cells present in the sample. A positive 
TPS using pembrolizumab’s companion diagnostic (antibody 22C3) is considered to be 
greater than 50% whereas for nivolumab (antibody 28-8), expression cut-offs are set at 
>1%, >5% or >10%. There are ongoing efforts to standardize and optimize PD-L1 
expression testing that include collaboration by the current ICI manufacturers to develop 
a universal PD-L1 testing platform (55).  
 
From a simply biological perspective, measuring the expression of the membrane-bound 
PD-L1 ligand should indicate tumors that will respond to therapy. However, limitations of 
this diagnostic test, such as timing of tissue acquisition, tumor heterogeneity, and timing 
of therapy relative to the inducible expression of PD-L1, raise the question as to whether 
expression of this molecule truly represents an anti-PD-1 or anti-PD-L1 responsive 
tumor (52). The Keynote-001 trial sought to correlate response to pembrolizumab with 
expression of PD-L1. In the melanoma arm, PD-L1 expression correlated with increased 
response rate in 49% compared with 13% of PD-L1 negative patients. The NSCLC arm 
of this study showed that, when PD-L1 expression on tumor cells was greater than 50%, 
response to pembrolizumab was predicted (67% PFS rate at 6 months). Of these 
patients, nearly 25% demonstrated PD-L1 protein on greater than 50% of tumor cells. 
For all-comers, response rate to pembrolizumab was about 19%. Importantly, median 
progression free survival (PFS) was 14.1 months in PD-L1 strongly positive patients 
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compared with 9.3 months in the weakly positive population (56). Response rates 
appear to be higher in tumors with elevated PD-L1 expression; however, some tumors 
that do not express PD-L1 still exhibit a response to therapy (57). Given these 
observations, measuring PD-L1 expression in a tumor cannot serve as an exclusionary 
predictive biomarker of response. Development of robust and validated biomarkers of 
response for ICI therapy has become a priority in this burgeoning field.  
Tumor-Infiltrating Lymphocytes and T-cell Receptors 
The abundance of tumor-infiltrating lymphocytes (TILs), specifically CD8+ T-cells 
expressing PD-1 or CTLA-4, have previously been identified as indicators of successful 
checkpoint inhibition (58, 59). There is a demonstrated difference, however, between 
increased populations of CD8+ T cells found at the invasive tumor margin versus those 
in the tumor itself with the former being the most closely associated with increased PD-
L1 expression. In addition, double positive PD-1+/CTLA-4+ CD8+ T cells within the 
melanoma were strongly associated with improved progression-free survival (PFS) (15.9 
mos vs. 9.9 mos, P=0.04) after anti-PD-1 therapy (59). Out of 15 patients in a validation 
cohort assessing the predictive ability of CD8+ T cells abundance, quantified CD8+ T 
cell density accurately predicted 4 out of 5 patients in the true progression group and 9 
out of 9 patients in the true response group. This data supports the notion that the 
abundance of TILs correlates with improved anti-PD-1 therapy response. Limitations of 
this assay include the need for assessing tumor tissue sample immediately prior to 
treatment. Most NSCLC patients undergo biopsies prior to resection and follow up with 
chemotherapy and/or radiotherapy. However, another biopsy would be necessary prior 
to addressing if the patient would be a candidate for ICI blockade. It is likely that the 
genomic and immune properties of the tumor would have changed since that initial 
biopsy so analyzing the original sample for TILs may not be accurate for subsequent 
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therapy. Further, it is cumbersome, and sometimes unreasonable, for a patient to 
undergo additional biopsies. 
 
T-cell receptor (TCR) diversity, or the range of difference TCRs expressed, plays a vital 
role in host defense (60). Diversity refers to the degree of dispersion between clonotypes 
or phenotype of a clone of cells. TCR diversity is generated by mutations resulting from 
recombination, random insertion, deletion and/or mismatch in the genes that encode T-
cell receptors, and there is potential to create between 106 to 1020 TCR clonotypes. TCR 
diversity has been examined before and after checkpoint inhibition to assess its impact 
on T-cell clonal populations and its effect on response (61-63). In both peripheral blood 
as well as tumor samples, a substantial increase in “diversity” of unique TCR V-beta 
CDR3 sequences after anti-CTLA-4 treatment was observed and presumably led to pro-
inflammatory or autoimmune hyper-responsiveness. Kvistborg et al monitored immune 
reactivity against a panel of 145 melanoma-associated epitopes in patients receiving 
anti-CTLA-4 treatment. Comparison of T cell reactivities prior to and after treatment for 
40 melanoma patients demonstrated that anti-CTLA-4 treatment induces a significant 
increase in the number of detectable melanoma-specific CD8 T cell responses (P 
=0.0009) (63). There was an increase in the total number of unique sequences but no 
one specific clone became predominant. In a study of patients with metastatic melanoma 
treated with PD-1 blockade, tumors that illustrated expansion of pre-existing TCRs, a 
more “focused” repertoire, were most likely to respond to therapy (58). The “focused” 
repertoire, defined as a more restricted TCR beta chain population, correlated with 
clinical response after pembrolizumab therapy (P=0.004).  Together, these data suggest 
a “diverse” profile of TCRs present in T cells infiltrating tumors is associated with 
improved response with anti-CTLA-4 treatment. A “focused” TCR profile is associated 
with improved response with anti-PD-1/PD-L1 blockade. Immuno-sequencing of TIL and 
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TCR diversity may be effectively used as predictors of response or for monitoring drug 
efficacy and toxicity. 
Mutational Burden 
Mutations give rise to the development of cancer; however, the degree of burden differs 
between different cancer types. Among all cancers, melanoma and lung cancers exhibit 
the highest mutational burden as determined by cataloging somatic mutations (64). 
Patients who harbor tumors exhibiting increased somatic mutations, such as 
nonsynonymous variants (a nucleotide substitution that alters the amino acid sequence), 
correlated with a benefit from CTLA-4 blockade (65). In a study of 64 malignant 
melanoma patients treated with anti-CTLA-4, whole-exome sequencing was conducted 
on tumor and matched blood samples. Somatic mutations and candidate neoantigens, a 
new antigen developed within the tumor the immune system has not previously been 
exposed to, were characterized. A discovery set of 11 patients who exhibited long-term 
clinical benefit and 14 patients who presented with minimal benefit were characterized. A 
neoantigen signature, determined by genome-wide somatic neoepitope analysis, 
predicted strong response to CTLA-4 blockade. This signature was validated in a set of 
39 patients. Tobacco smoke, which contains carcinogens such as arsenic and benzene 
that induce mutations, was associated with benefit of PD-1 blockade in lung cancer 
patients (66). A smoking signature was determined utilizing whole-exome sequencing of 
NSCLC samples in two independent cohorts, n=16 and n=18. The smoking signature, 
identified as transversion high (i.e. the substitution of a purine for a pyrimidine DNA base 
or vice versa) and is associated with elevated neoantigen burden, lead to improved 
objective response, durable clinical benefit, and progression-free survival (66). The 
observation that nonsynonymous mutation burden is associated with anti-PD-1 efficacy 
is consistent with the hypothesis that APC recognition of neoantigens, formed because 
of somatic mutations, is important for the activity of anti–PD-1 therapy. 
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DNA repair mechanism mutations, especially in the mismatch repair (MMR) pathway, 
also contributed to the mutational burden leading to improved response to certain 
therapies. Patients exhibiting MMR-deficient tumors, which occurs in a small population 
of cancers, benefited from anti-PD-1 treatment (67). In 41 patients with metastatic 
carcinoma with or without MMR-deficient disease, anti-PD-1 treatment was 
administered. The 20-week immune-related progression free survival rate showed an 
improved response in patients with the MMR-deficient cancer (78% vs. 11%). Whole-
exome sequencing revealed 1,782 somatic mutations per tumor in the MMR-deficient 
tumors compared to 73 in the MMR-proficient tumors (P=0.007). The resulting tumors 
express high levels of PD-L1 and possess a cytokine-rich microenvironment with 
immune infiltrates expressing PD-1, CTLA-4 or LAG-3, signaling a primed response. 
Since then, this study has been expanded to evaluate the efficacy of PD-1 blockade in 
patients with advanced MMR-deficient cancers across 12 tumor types and is currently 
still ongoing (68). Eighty-six patients with at least one prior therapy and evidence of 
progressive disease underwent treatment with a PD-1 inhibitor. Mismatch-repair 
deficiency was identified in all patients using either polymerase chain reaction or 
immunohistochemistry.  The study is ongoing and has yet to reach the primary endpoint 
of overall survival. In May of 2017, Keytruda (pembrolizumab) received an indication for 
the treatment of adult and pediatric patients with unresectable or metastatic solid tumors 
that have a microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) 
hypermutated malignancy (69). These works have collectively led to the fast-tracked 
approval for the first cancer treatment for any solid tumor with a specific genetic feature.  
Inflammatory Gene Signatures 
Other factors inherent to the nature of the tumor microenvironment may determine 
resistance or susceptibility to immunotherapy. Gamma interferon-inducible genes have 
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been highlighted in the literature in defining a “hot” tumor – or a tumor with an interferon 
responsive signature (70, 71). Class II MHC-positive melanomas that have this 
interferon responsive signature respond to PD-1 blockade. Other studies show the loss 
of this signature reduces efficacy of treatment (72). First, whole exome sequencing of 
tumors from 16 patients with melanoma who did not respond to ipilimumab therapy and 
had reduced overall survival, identified multiple-copy-number alterations resulting in the 
loss of interferon gamma pathway genes, including IFNGR1 (73). Next, patients from the 
KEYNOTE-012 (NCT01848834) study that assessed the use of pembrolizumab for the 
second-line treatment of head and neck squamous cell carcinoma (HNSCC) were tested 
using 4 multi-gene expression signatures (74). These 4 gene sets included “IFN-γ” (6-
gene), “TCR signaling” (13-gene), “expanded-immune” (18-gene) and “de novo” (33-
gene). The “IFN-γ” set included CXCL9, CXCL10, IDO1, IFN- γ, HLA-DRA, and STAT1. 
All 4 sets showed strong association with PFS (P<0.0005) with “IFN-γ” the top performer 
with a positive predictive value (PPV) for response of 40.0%, and negative predictive 
value (NPV) of 95.0%. In a third study, patients treated with atezolizumab, a PD-L1 
inhibitor, demonstrated an increased response when an INF-γ gene signature was highly 
expressed (75). In this open-label phase 2 trial, 286 patients with NSCLC previously 
treated with platinum chemotherapy were to be randomized to receive atezolizumab or 
docetaxel therapy. Overall survival for the atezolizumab group was 12.6 months (95% CI 
9.7-16.4) versus 9.7 months (95% CI 8.6-12.0) for the docetaxel group. More 
impressively, in an additional exploratory analysis, patients treated with atezolizumab 
with high T-effector-interferon-γ-associated gene expression (Teff High) improved overall 
survival (HR 0.43; 95% CI 0.24–0.77), the best improvement in response. End of the 
study was reached before overall survival could be assessed. Teff high was associated 
with a median follow-up of 15 months where Teff low had a median follow-up of 10 
months (75). Another study assessed the regulation of a library of 209 different cytokines 
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from the human cytokine library, IFN-γ  stood out due to its autocrine mechanism to 
elevate STAT1 and induce internalization of gp130, a component of many heterodimeric 
cytokine receptors (76). 
 
These studies have identified the impact of inflammatory genes and pro-inflammatory 
cytokines on immune response. IFN-γ may be critical in this process due to its 
hypothesized role as a master checkpoint regulator for many other cytokines. STAT 
family proteins generally reside in the cytoplasm as inactive homodimers (77). Receptor-
associated JAKs become activated upon ligand binding leading to phosphorylation of 
specific receptor tyrosine residues. These residues direct SH2-dependent recruitment of 
specific STATs which as then activated and released and reorient into antiparallel 
dimers where the SH2 domain on one STAT binds to the phosphotyrosine on the other 
STAT. Activated STAT dimers translocate into the nucleus. In response to IFN-γ, STAT3 
protein phosphorylation is reduced in favor of increasing both expression and 
phosphorylation of STAT1. Once phosphorylated, STAT1 proteins form homo- or 
heterodimers and translocate to the nucleus where they act as transcription activators. 
This simple elevation of STAT1 and down-regulation of STAT3 by IFN-γ interferes with 
multiple cytokines using STATs as key signal transducers.  
Gut Microbiome 
Several studies have shown that the intestinal microbiome may modulate the anticancer 
effect of certain chemotherapies, such as cyclophosphamide (78-80). 
Cyclophosphamide alters the composition of the gut microbiota, specifically translocating 
select Gram positive bacteria into secondary lymphoid organs leading to generation of T 
helper 17 (Th17) cells and memory Th1 immune responses. The specific Gram-positive 
bacteria identified were Lactobacillus johnsonii, Lactobacillus murinus and Enterococcus 
hirae. When assessing the therapeutic efficacy of anti-PD-1 treatment alone or in 
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combination with anti-CTLA-4 treatment in mice with sarcoma or melanoma, mice were 
raised in specific pathogen-free conditions and then either treated for 14 days with 
broad-spectrum antibiotics (ampicillin, colistin, streptomycin) or left untreated (81). Mice 
that were exposed to antibiotics exhibited a worse prognosis when treated with an ICI. 
The researchers also examined the impact of antibiotics on 249 human patients with 
NSCLC, renal cell carcinoma (RCC) or urothelial carcinoma treated with ICI.  Patients 
exposed to antibiotics two months prior to ICI treatment or one month after exhibited 
decreased PFS (3.5 mos vs. 4.1 mos, P=0.017) and decreased overall survival (11.5 
mos vs. 20.6 mos, P<0.001) as compared to patients with no exposure to antibiotics. 
Analysis of the composition of the gut microbiota implicated A. muciniphila with favorable 
clinical outcome (P=0.004). In a separate prospective study, microbiome samples were 
collected from patients with metastatic melanoma patients prior to treatment with anti-
PD-1 therapy (82). Thirty-five patients were classified as non-responders and fifty-four 
classified as responders based on Response Evaluation Criteria in Solid Tumors 
(RECIST) criteria at 6 months after treatment initiation. Diversity of the gut microbiome 
was significantly higher in the responder group compared to the non-responders 
(P<0.001). R. faecalibacterium was abundant in the responder group while Bacteroides 
thetaiotaomicron was found present in non-responders. R. faecalibacterium in the gut 
was associated with higher levels of effector CD4+ and CD8+ T cells in the systemic 
circulation with a preserved cytokine response to anti-PD-1 therapy, whereas patients 
with a higher abundance of Bacteroides in the gut microbiome had higher levels of 
regulatory T cells (Treg) and myeloid derived suppressor cells (MDSC) in the systemic 
circulation, with a blunted cytokine response. The proposed mechanism by which the gut 
microbiome enhances systemic and anti-tumor immune responses suggests that 
increased antigen presentation improves effector T cell function in the periphery and the 
tumor microenvironment. Specific bacteria, such as E. hirae and A. microsciphilia, are 
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also associated with obesity and diabetes. Previous microbiome-wide association 
studies not only linked cancer to the gut microflora but also to obesity, cardiovascular 
disease, and type 2 diabetes (83).  These data prompt the question as to whether the 
inflammatory states induced by these chronic conditions give rise to the microbiome that 
impacts ICI treatment. 
 
D. BIOMARKERS OF RESPONSE IN PERIPHERAL BLOOD 
 
In the clinical setting, the ease of access to a patient sample with which to measure a 
potential biomarker is weighed heavily in addition to its precision of use. Currently, only a 
tumor-derived biomarker of response has been approved by the FDA for anticipating 
response to ICI. PD-L1 expression is typically assessed from a biopsy of the solid tumor 
and, as discussed earlier, the timing of tissue acquisition, tumor heterogeneity, and 
timing of therapy affect the PD-L1 expression value. PD-L1 expression is a dynamic 
parameter that cannot be adequately represented with a single snapshot (84). Liquid 
biopsies, in addition to being repeatable and easily accessible, allow for characterization 
of the dynamic changes of the tumor. Circulating tumor cells (CTCs) sampled from the 
primary tumor site likely share the immune escape mechanisms (85). In addition to PD-
L1 expression, peripheral blood may allow for identification of other immune factors 
influencing the response to ICIs. Identification of a robust biomarker that is more readily 
available from peripheral blood would, not only avoid the need for additional biopsies, 
but could then be streamlined in the clinic to allow for more efficient treatment.  
Peripheral Immune Populations  
Tumor immune cell subtypes have been assessed within the tumor microenvironment, 
and specific cells are associated with improved response to ICIs (58, 59). These are 
typically measured from a tumor biopsy of the primary or metastatic tumor site. However, 
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these sites are often not very accessible and so immune cell subpopulations in the 
periphery can be explored using multi-parametric flow cytometry (86, 87). In a study of 
209 advanced melanoma patients treated with ipilimumab, baseline frequencies of 
myeloid-derived suppressor cells (MDSC), regulatory T cells (Treg), serum lactate 
dehydrogenase (LDH), eosinophil count, and other clinical characteristics were 
measured then analyzed by Cox regression analysis to identify factors associated with 
improved overall survival (88). The study, conducted in two phases, aimed to first 
identify biomarker candidates that best fit a prognostic model and in the second phase 
validate the biomarker combination. Of 28 potential variables measured, a six 
biomarkers signature was confirmed to predict improved survival (low LDH count, 
elevated eosinophils, low absolute monocytes, high absolute lymphocytes, low 
Lin−CD14+HLA-DR-/low MDSC frequencies, and elevated CD4+CD25+FoxP3+ Treg 
frequencies). The immunological rejection of cancer is dependent on the balance of 
interactions between T cells and regulatory cells (89). Eosinophils, lymphocytes, 
monocytes, Tregs and MDSCs are components involved in this regulatory network. 
Eosinophils are multifunctional white blood cells with cytosolic, large granules containing 
a variety of cytokines and chemokines. These cells play a part in tumor surveillance and 
tumor rejection. MDSCs and Tregs suppress the functions of T cells potentially 
counteracting the benefit of ICIs. 
 
Another study investigating peripheral markers of response suggests that CD4+ T cells 
expressing PD-1 in peripheral blood are associated with poor clinical outcomes for 
NSCLC patients treated with a PD-1 inhibitor (90). Peripheral blood mononuclear cells 
(PBMC) retrieved from 42 NSCLC patients at diagnosis and from an additional 25 
healthy donors were assessed for frequency of PD-1 expression on both CD4+ and 
CD8+ T cells. PD-1+ CD4+ T cells were elevated among NSCLC patients as compared 
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to healthy donors (13.3% vs. 8.8%, p=0.0045). However, there was no difference in PD-
1 expression on CD8+ T cells among both populations. CD4+ T cell subgroups defined 
as high-PD-1 (PD-1 > 12.27%) and low PD-1 (PD-1 <12.27%) were based on the mean 
expression levels of the 42 NSCLC patients. Lower rates of both OS and PFS were 
associated with the high-PD-1 groups as compared to the low-PD-1 group (median OS: 
397 days vs. 721 days, p=0.028; median PFS: 88 days vs. 391 days, p=0.044). In 
addition, the elevated PD-1 expression on either T cell subset isolated from peripheral 
blood was not associated with PD-L1 expression on tumor tissue.  These results suggest 
a biomarker of response to checkpoint inhibition could be established based on cell 
surface markers of immune cell subsets in peripheral blood. 
Peripheral Immunoscore 
As discussed earlier, it has been reported that patients with high baseline TILs are 
associated with improved response to ICI therapy. Immunoscores are a signature of 
immune cell populations that indicate disease responsive to ICI treatment. Single 
parameters, like tumoral PD-L1 expression, are limited in their prognostic value, but the 
combination and interaction of several parameters may establish a robust predictor of 
response. Tumor immunoscore analyses have been primarily conducted on biopsies of 
primary or metastatic tumor lesions, but there may be promise in completing the same 
analyses of immune cell subsets in the periphery (91, 92). Further, others have 
hypothesized that immune cells in peripheral blood may be different among patients with 
metastatic disease leading to a different response to immunotherapy. Single marker 
studies have assessed the prevalence of circulating CCR7+ CD8+ T lymphocytes in 
head and neck cancers, or MDSC in advanced melanoma in relation to PFS (93, 94). 
However, a multivariate panel that measures immune cell subsets is more likely to be an 
efficient prognostic assay than any single immune effector cell (95). In a study by 
Farsaci et al, peripheral immunoscores were established from analysis of PBMC prior to 
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treatment with immunotherapy to define whether there was a correlation of what with 
efficacy of immune-based treatment (87). PBMC analyzed were collected from two 
sources: patients with metastatic cancer randomized to receive docetaxel with or without 
PANVAC vaccine or prostate cancer patients with metastatic bone lesions randomized 
to receive radionuclide with or without PROSTVAC vaccine (96, 97). PANVAC is a 
poxviral-based vaccine therapy targeting carcinoembryonic antigen (CEA) and mucin-1 
in carcinoma. PROSTVAC is prostate specific antigen (PSA)-targeted immunotherapy. A 
peripheral immunoscore accounting for "classic" immune cell types (CD4, CD8, NK cells, 
regulatory T cells, and MDSCs) revealed no differences in progression-free survival 
(PFS) for either arm in both trials. Importantly, an immunoscore developed from a 
“refined” subsets of immune cells with a phenotype reflecting immune function revealed 
statistically significant differences in PFS. Peripheral immunoscores have yet to be 
assessed at baseline of PD-1 or PD-L1 inhibitor treatment, and so different immune cell 
properties may be better predictive of interactions in the PD-1/PD-L1 pathway. The 
clinical application of this assay is promising, but further validation in all ICI pathways is 
required. 
Tumor-derived Exosomes 
Tumor cells produce more extracellular vesicles than normal cells, which may explain 
why plasma exosomes are substantially higher in patients with cancer than in normal 
donors (98). Tumor-derived exosomes, or “TEX”, carry molecular cargo from the tumor 
microenvironment and can also deliver suppressive or stimulatory signals to immune 
cells. TEX are typically isolated from supernatants of cultured human or murine tumor 
cell lines using ultracentrifugation or sucrose density gradient centrifugation; however, 
this method is time-consuming and is not reproducible in a scaled-up environment for 
exosome recovery from numerous human specimens. Taylor, et al. developed a size 
exclusion chromatography (SEC) approach to readily recover intact TEX from small 
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volumes of plasma (99). TEX do mirror some of the key molecules characteristic of the 
parent tumor cell and thus may serve as a surrogate of the tumor microenvironment 
(100). As such, they carry tumor-associated antigens, major histocompatibility complex 
(MHC) class I and II molecules, and a variety of cytokines that enable TEX to stimulate 
or suppress immune cells. However, in another study, antibody-based therapies such as 
ICIs can be less effective because TEX carry the antigen targets of ICI and can act as a 
sponge to “soak” up the antibodies. Therefore, diminishing concentrations of drug are 
measured at the tumor site (101). TEX may be used as a predictive model for treatment 
due to it serving as a surrogate for the tumor microenvironment; however, further 
validation is required. 
Angiopoietin-2 
Angiogenesis, the formation of new vasculature, is a hallmark of cancer. Angiogenic 
factors, such as angiopoietin-2 (ANGPT2), play significant roles in the inhibition of 
immune activities by inhibiting dendritic cell maturation, tumor infiltration by lymphocytes, 
promoting Tregs and MDSC expansion (102-104). Increased expression of Tregs and 
MDSCs directly suppresses the immune response. ANGPT2 is upregulated in tumor 
vasculature and confers resistance to anti-angiogenesis therapy targeting vascular 
endothelial growth factor (VEGF) (105). Although ANGPT2 had been previously 
identified as a prognostic marker of outcome. For certain cancers being treated with anti-
VEGF therapy, it may have the potential to be used as a predictive biomarker for 
immune checkpoint inhibition. In metastatic melanoma patients, both high pretreatment 
concentrations and increases in serum ANGPT2 during treatment were associated with 
reduced overall survival in CTLA-4 and PD-1 blockade–treated patients (106). Further 
data indicates that the features of tumor blood vessels can limit the anti-tumoral 
functions of T cells, specifically cytotoxic CD8+ T cells. Dual blockade of VEGF and 
ANGPT2 as a tumor-conditioning strategy has been shown to increase the efficacy of 
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anti-PD-1/PD-L1 therapy in cancer (107). In both transgenic and transplant mouse tumor 
models, dual blockade delayed tumor progression and was found to expand tumor-
associated-macrophages (TAMs) and dendritic cells. In addition, the proportion of CD8+ 
TILs were increased. When PD-1 blockage was introduced into the mouse model, the 
anti-tumoral activity of the dual blockade was further enhanced. The harmonizing actions 
of the antiangiogenic therapy with immune checkpoint inhibition may allow for synergistic 
efficacy in treatment. ANGPT2 addresses a lot of the criteria of a robust peripheral 
biomarker of response. It is easily sampled, validated in multiple tumor types in different 
combinations of ICIs, and is continually monitored during treatment. A comparison study 
of ANGPT2 levels and PD-L1 expression is needed to determine which one is a more 
robust biomarker. 
 
E. RESEARCH PROPOSAL OVERVIEW 
 
The identification of potent immune response inhibitory pathways, regulated by 
interactions managed by PD-1 and CTLA-4, have paved the way for revolutionizing 
immunotherapy for cancer treatment. Despite the development of immunotherapies 
utilized in the clinical setting today, we still understand little of the molecular mechanisms 
that initiate or subdue T cell exhaustion. With the increasing use of these agents in the 
clinic as well as many other ICIs currently in the pipeline, the demand for a validated and 
robust biomarker of response is high. Due to the potential for long durable responses, a 
validated and robust biomarker of response is needed to increase the rate of long-term 
responders from merely 20%. Further analyses of peripheral immune cells, cytokine 
production and the mechanisms influencing T cell exhaustion will be critical to defining a 
peripheral blood biomarker that is accessible, reproducible and validated.  
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I sought to identify a biomarker of response to ICIs that improves patient care using a 
combination of healthcare outcomes and molecular markers that correlate to therapeutic 
efficacy. Two testable research hypotheses were developed: First, I proposed that 
chronic inflammatory pretreatment comorbidities would impact baseline immune 
system function and regulation of response to cancer.  This includes 
hyperlipidemia, hypertension, diabetes mellitus and obesity; collectively known as 
metabolic syndrome (MetS) as well as chronic obstructive pulmonary disorder 
(COPD). The comorbid history of MetS and/or COPD among NSCLC patients 
correlates with response to immune checkpoint inhibitor treatment. This 
hypothesis was assessed in both a retrospective single-center study as well as a 
national health outcomes observational study. Secondly, MetS and COPD 
comorbidities will provide additional understanding of the underlying biology of 
immune cell subsets and cytokine profiles in the periphery that influence 
response to ICIs. 
 
The work herein documents the use of translational research and 
pharmacoepidemiology utilized to improve the clinical use of ICIs in cancer through 
improving patient selection via a more robust biomarker of response. 
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         Table 1.1:  Overview of candidate biomarkers of response for immune checkpoint inhibitors. 
TYPE BIOMARKER 
DISEASE 
SETTING TREATMENT 
CUT-
OFF/MEASURE CLINICAL SIGNIFICANCE 
Tumor-
derived 
Tumor-
Infiltrating 
Lymphocytes 
(TILs) 
Melanoma/
NSCLC Anti-PD-1 20% 
PD-1+/CTLA-4+ CD8+ T Cells 
>20% were associated with 
improved PFS (15.9 Mo vs. 9.9 
Mos, P=0.04).20 
  T-Cell Receptor (TCR) Diversity Melanoma Anti-CTLA-4 "Diverse" 
Pre- and posttreatment T cell 
reactivity after anti-CTLA-4 
treatment show significant 
increases in number of detectable 
melanoma-specific CD8+ T cell 
responses (P=0.0009).21,22 
    Melanoma Anti-PD-1 "Focused" 
A more restricted TCR beta chain 
usage (less diverse and more 
clonal) correlated with clinical 
response after pembrolizumab 
therapy (P=0.004).19 
  
Mutational 
Burden Melanoma Anti-CTLA-4 > 100 mutations 
Patients with long-term clinical 
benefit (PFS > 6 months), had 
increased mutational burden 
(P=0.04).25 
  
  
NSCLC Anti-PD-1   
Greater PFS in those with higher 
nonsynonymous mutation burden 
compared to those with lower 
nonsynonymous mutation burden 
(HR 0.19, 95% CI 0.08–0.47, P = 
0.0004).26 
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  Mismatch Repair (MMR)  Multiple Anti-PD-1 MMR-deficient 
Response rate and PFS for MMR-
deficient colorectal cancers were 
40% and 78% compared to 0% and 
11% for MMR-proficient colorectal 
cancers, respectively.27 Current 
study expanded for 12 more tumor 
types and is ongoing.28 
  IFN-γ Gene Signature Melanoma Anti-CTLA-4 
High expression of 
IFN-γ gene 
signature 
Strong associated with improved 
PFS (P=0.0005). PPV of 40.0%, 
NPV 95.0%.33 
    NSCLC Anti-PD-L1 
High expression of 
IFN-γ gene 
signature 
NSCLC patients treated with 
atezolizumab with high T-effector-
IFN-γ-associated gene expression 
(Teff  IFN-γ High) improved overall 
survival (HR 0.43; 95% CI 0.24–
0.77), compared to Teff  IFN-γ Low 
(HR 1.10, 95% CI 0.68-1.76).34 
  Gut Microbiome mRCC/NSCLC Anti-PD-1 
E. hirae & A. 
microsciphilia 
Presence of certain gut flora has 
been associated with improved 
efficacy of nivolumab. In addition, 
antibiotic therapy 2 months or or 
month after nivolumab-treatment, 
resulted in reduced PFS (2.3 Mos 
vs. 9.1 Mos, P<0.001).39 
Peripheral 
Blood 
Immune Cell 
Populations NSCLC Anti-PD-1 
PD-1 >12.27% on 
CD4+ T Cells 
Lower rates of both OS and PFS 
were associated with the high-PD-1 
groups as compared to the low-PD-
1 group (median OS: 397 days vs. 
721 days, P=0.028; median PFS: 
88 days vs. 391 days, P=0.044).45 
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  Peripheral Immunoscore Breast 
Immunotherap
y Vaccines 
Score based on % 
CD4, % CD8, % 
Treg, %MDSC, 
%NK, Ratio 
CD4:Treg, Ratio 
CD8:Treg, Ratio 
CD4:MDSC, Ratio 
CD8:MDSC 
Peripheral immunoscore of refined 
subsets of immune cells revealed 
statistically significant differences 
in PFS (P < 0.001) for breast 
cancer patients receiving docetaxel 
plus immunotherapy vaccine and in 
prostate cancer patients receiving 
radionuclide plus immunotherapy 
vaccine (P = 0.004).43 
  
Tumor-derived 
Exosomes 
(TEX) 
Multiple N/A   
TEX can act as a snapshot of the 
tumor microenvironment but easily 
assessed in peripheral blood.55 
  Angiopoietin-2 (ANGPT2) Melanoma 
Anti-CTLA-4/ 
Anti-PD-1 
ANGPT2 <  3,175 
pg/mL 
Patients with low pretreatment 
ANGPT2 experienced improved 
survival as compared to those with 
low ANGPT2 concentrations (7.9 
Mos vs. 34.6 Mos, P<0.0001).61 
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CHAPTER 2  
A. OVERVIEW 
 
The utilization of pharmacoepidemiological techniques was a familiar task to myself and 
to our laboratory. To assess the ability of measuring survival and response from 
exposure to a certain treatment, we evaluated the role of statins in the cancer 
population.  Our laboratory has prior experience in the analysis national healthcare 
claims datasets, such as Truven Marketscan (108). The role of HMG-CoA reductase 
inhibitors (statins) in chemoprevention and cancer treatment has been deliberated in the 
literature (109-113) as well as the mechanism by which they may exert their effect and 
improve overall survival (OS) in cancer patients (114-117).  Recent cohort studies have 
shown that current statin use is associated with significantly lower risk of cancer death 
(111) while other studies have shown that statin use following diagnosis can reduce 
cancer-specific mortality in breast (118), colon (119, 120), and lung cancer (121) 
patients. However, some skepticism remains as mitigation of all confounding factors is 
not possible with cohort or pharmacoepidemiological studies (122, 123). Prospective 
evaluation of statins as monotherapy in cancer has been attempted, but a recent review 
of clinical trials of statin monotherapy in cancer revealed little effect (124). In contrast, 
prospective trials using a combination of statin with chemotherapy have shown improved 
survival in cancer patients (125-129). Given the relative safety profile of statins, rational 
combination therapies may provide cancer patients clinical benefit at the expense of 
minimal toxicity risk.  
 
Mechanistically, statins inhibit 3-hydroxy-3-methylglutarylcoenzyme A (HMGCoA) 
reductase, the rate-limiting enzyme of the mevalonate pathway, which ultimately 
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produces cholesterol along with isoprenoids; intermediate pathway metabolites such as 
farnesyl pyrophosphate (FPP) and geranyl geranyl pyrophosphate (GGPP) (130, 131). 
The physiological importance of isoprenoids in normal and cancer cells is critical for 
facilitating membrane anchoring of numerous signaling molecules including G-proteins 
such as Ras and Rho (132). Furthermore, constitutive activation of signaling pathways in 
cancer is dependent on cholesterol availability for formation of lipid rafts (133, 134). 
Recognition of the biological importance of FPP and GGPP led to drug development 
efforts of isoprenylation enzyme inhibitors (135, 136), which ultimately stalled in early 
phase studies due to toxicity and lack of efficacy. Pharmacologically, bisphosphonates 
also act as isoprenylation inhibitors (137, 138) and are widely used to inhibit bone 
resorption and treat osteoporosis. Bisphosphonates have also been used extensively to 
treat cancer patients with bone metastases (139-142). Their effect on reducing bone 
metastasis is significant and is consistent with the observations that they cause 
apoptosis in tumor cells via inhibition of the mevalonate pathway as well as tumor cell 
invasion in vitro (143, 144).  Reduced cholesterol levels trigger a negative feedback 
loop, which ultimately leads to the upregulation of mevalonate pathway genes via the 
transcriptional activity of SREBP transcription factors (145, 146). Based on this 
understanding, preclinical studies have demonstrated synergy when combining statins 
with bisphosphonates (114, 143, 147-151) and most recently dipyridamole, which has 
been shown to inhibit SREBP2 (152, 153).  Thus, the use of combination therapies that 
can amplify the effect of statins or abrogate the development of statin related resistance 
may lead to synergistic clinical combinations. Here we used a large dataset of health 
claims to test the hypothesis that statins alone, or in combination with potentially 
synergistic therapies prolong survival in cancer patients. The combination of 
ADAPTED FROM: El-Refai et al, JCO Clinical Cancer Informatics (2017) 
DOI:10.1200/CCI.17.99919 
 
33 
   
  
epidemiological evidence and preclinical data may provide strong rational for future 
prospective clinical studies.  
 
B. METHODS 
 
We used the Truven Health MarketScan Commercial Claims and Medicare Supplemental 
Databases. The Marketscan database includes approximately 40 million individuals from 
over 160 large employers and health plans across the US and includes healthcare 
claims with diagnosis and procedure codes for medical encounters and all prescription 
medication fills. Data are de-identified in compliance with the Health Insurance 
Portability and Accountability Act regulations (HIPAA) and the University of Kentucky 
Institutional Review Board approved the use of the database for this study. 
Patient Selection 
Adults aged 18 years and older diagnosed with cancer between January 1, 2010 and 
November 31, 2013 were identified using ICD-9 codes in the primary or secondary 
positions. Patients with prostate and breast cancer were excluded due to the use of 
hormonal therapy affecting risk for thromboembolism. Patients were diagnosed with one 
of the following types of cancer: Stomach (ICD-9 codes: 151.xx), Pancreatic (157.xx), 
Brain (191.xx), Lung (162.2 – 162.9), Renal (189.0, 189.1), Lymphoma (200.xx – 
202.xx), Leukemia (204.xx – 208.xx), Myeloma (203.0x), Colorectal (153.xx, 154.xx), or 
Gynecological (179.xx, 180.xx, 182.xx, 183.xx). At least 2 inpatient or outpatient 
diagnoses within 14 days were required, and the date of the first qualifying diagnosis of 
cancer was defined as the index date. Patients were required to have at least 12 months 
of pre-index and a minimum of one-month post-index continuous enrollment in the 
database.  
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Exposure groups were defined as: statin users with no history of non-statin cholesterol-
lowering medication use; non-statin cholesterol-lowering medication users with no 
history of statin use (“non-statin users,” active control group); and those with no history 
of statin or non-statin medication use (“non-users,” control group). Medication use was 
based on having at least 90 cumulative days supplied in the 6 months prior to diagnosis. 
Specific statins include lovastatin, pravastatin, simvastatin, rosuvastatin, atorvastatin, 
fluvastatin and pitavastatin. Non-statins include fibric acid derivatives, bile acid 
sequestrants, and nicotinic acid.  
Measures 
Patient demographic characteristics included age, gender, geographic region and urban 
residence. Clinical characteristics measured during the 12-month pre-index period 
included the Charlson Comorbidity Index (CCI) and Elixhauser comorbidities (Elix) (154, 
155).  These include 17 and 31 categories of comorbid conditions, respectively, and are 
widely used for risk adjustment with health outcomes data. Additional medications 
accounted for in the pre-index period included anticoagulants, antihypertensives, 
antiplatelet, antiarrhythmics, and digoxin. Presence of metastatic disease was assessed 
on the index date.    
Statistical Methods 
Pairwise analyses were done between: statins vs. non-statins, statins vs. non-users, and 
non-statins vs. non-users. Propensity score matching was conducted using baseline 
comorbidities, medications, and demographic information to achieve balance between 
treatment groups. Propensity scoring mimics the randomization process of a clinical trial 
so that each matched pair has the same baseline probability to receive either treatment 
(156-158). Matched pairs should be similar in all baseline characteristics. Patients with 
the same cancer type were matched using a greedy, nearest neighbor algorithm with a 
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caliper set at 0.2 times the standard deviation of the propensity scores in the sample, 
allowing for up to five matches for each treated person (159). Standardized differences 
were calculated and shown in Appendix A. A standardized difference of <0.10 is 
generally considered to be non-significant (160).  To address any residual confounding 
after propensity score matching, covariates were also incorporated in the final regression 
models (157). The final model included the following adjustment covariates: age, CCI 
score, region, anticoagulants, antihypertensives, antiplatelets, antiarrhythmics, digoxin, 
elixhauser index comorbidities and pre-index history of CHD, DVT, PE, atrial thrombosis 
and MI. Two sample t-test and chi-square tests were conducted to assess significant 
differences between treatment groups before and after matching. 
 
The study cohort was followed until subjects died, were lost to follow-up due to loss of 
enrollment in the dataset, or the end of the study data. Cox proportional hazard 
regression models, accounting for correlation within matched pairs, were used to assess 
risk of death within one year of diagnosis among all cancers and then stratified among 
each cancer. Follow-up was terminated for those surviving beyond one year and were 
censored. Hazard ratios (HR) and 95% confidence intervals (CI) are reported. A p-value 
of <0.05 is considered statistically significant. All matching and statistical analyses were 
conducted in SAS. 
Subgroup Analyses 
A sensitivity analysis assessing the influence of age as an effect modifier was 
completed. Comparisons were made within age groups of less than 65 years old, 65-75 
and greater than 75 as these groups may have different treatment patterns, responses 
and baseline survival prior to cancer diagnosis. The effect of dose intensity was 
evaluated by limiting the statin cohort to moderate or high dosage statins and comparing 
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again with non-statins and non-users (161). Patients remaining on statin therapy after 
cancer diagnosis were assessed by observing the proportion of days where medication 
was on-hand in the post-index period until end of follow-up. Statins were compared 
individually and by type to ascertain differences among outcomes. Natural statins 
include lovastatin, pravastatin and simvastatin and synthetic statins include rosuvastatin, 
atorvastatin, fluvastatin and pitavastatin (162). Patients using bisphosphonates or 
dipyridamole, alone or in combination with statins, were compared to non-users to 
assess effectiveness or synergy in terms of survival. Bisphosphonates assessed in the 
analysis were alendronate sodium, etidronate disodium, ibandronate sodium, 
pamidronate disodium, risedronate sodium and zoledronic acid. Bisphosphonates and 
dipyridamole were subject to the same requirement of having at least a 90 cumulative 
days supplied in the 6 months prior to cancer diagnosis. For all subgroup analyses, all 
cohorts were rematched via propensity score methods described above. 
 
C. RESULTS 
 
Table 2.1 displays the baseline demographic and clinical characteristics of the study 
population by treatment group. Due to the enrollment criteria, there were no missing 
values on covariates used for propensity-score matching or survival analyses. Eligibility 
criteria were met by 312,907 cancer patients. Three treatment groups were established 
as outlined in the CONSORT diagram (Figure 2.1): statin-users (n=65,440), non-statin-
users who received non-statin cholesterol lowering medications (n=9,289) and non-users 
(n=226,007). There were 8,198 patients who passed away within one year of diagnosis, 
1,702 from the statin-users cohort, 216 among the non-statins users and 6,280 from the 
no treatment cohort. The cohort contributed an average follow-up time of 359 days (SD 
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39.3) with no differences between cancer types or treatment groups. The mean 
(standard deviation, SD) age of patients in the statins, non-statins and non-users cohorts 
was 74.2 (7.8), 71.8 (9.3) and 60.8 (14.1), respectively. In all treatment groups, lung, 
lymphomas, and colorectal cancers accounted for the top three diagnosed cancers 
whereas stomach, pancreatic, and brain cancers were the least diagnosed.  
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Table 2.1:  Baseline demographic and clinical characteristics of all cohorts included in 
the analysis. 
  Treatment Group 
Statins 
N=65,440 
Non-Statins 
N=9,289 
Non-Users 
N=226,007 
Characteristic Mean Std. Dev Mean Std. Dev Mean Std. Dev 
Age 74.72 7.84 71.79 9.33 60.8 14.08 
CCI 5.1 3 5.09 3 4.34 2.9 
  N % N % N % 
Gender (Male) 31,006 47.4% 4,046 43.6% 129,670 57.4% 
Urban 55,634 85.0% 7,758 83.5% 188,958 83.6% 
CHF 10,456 16.0% 1,255 13.5% 16,016 7.1% 
Arrhythmias 18,941 28.9% 2,364 25.4% 37,160 16.4% 
Valvular disease 10,749 16.4% 1,364 14.7% 19,602 8.7% 
Pulmonary 
Circulation 
3,008 4.6% 414 4.5% 7,496 3.3% 
Peripheral 
Vascular 
20,169 30.8% 2,570 27.7% 33,064 14.6% 
Hypertension 
uncomplicated 
46,024 70.3% 6,476 69.7% 108,426 48.0% 
Hypertension 
complicated 
7,300 11.2% 1,026 11.0% 12,416 5.5% 
Paralysis 712 1.1% 86 0.9% 2,316 1.0% 
Other 
neurological 
5,282 8.1% 666 7.2% 16,383 7.2% 
Chronic 
pulmonary 
19,996 30.6% 2,599 28.0% 50,536 22.4% 
Diabetes 
(Uncomplicated) 
21,848 33.4% 3,625 39.0% 41,544 18.4% 
Diabetes 
(Complicated) 
7,598 11.6% 1,230 13.2% 10,859 4.8% 
Hypothyroidism 9,122 13.9% 1,378 14.8% 31,244 13.8% 
Renal failure 8,605 13.1% 1,433 15.4% 14,718 6.5% 
Liver disease 5,558 8.5% 943 10.2% 25,865 11.4% 
Peptic ulcer 
disease 
1,278 2.0% 184 2.0% 3,776 1.7% 
HIV/AIDS 49 0.1% 25 0.3% 1,035 0.5% 
Metastatic 
Cancer 
9,925 15.2% 1,362 14.7% 40,686 18.0% 
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Rheumatoid 
Arthritis 
3,231 4.9% 497 5.4% 11,365 5.0% 
Coagulopathy 3,775 5.8% 527 5.7% 13,017 5.8% 
Obesity 3,486 5.3% 676 7.3% 16,740 7.4% 
Weight Loss 4,981 7.6% 656 7.1% 16,717 7.4% 
Fluids and 
Electrolytes 
9,179 14.0% 1,228 13.2% 30,267 13.4% 
Blood Loss 
Anemia 
4,005 6.1% 493 5.3% 10,277 4.5% 
Deficiency 
Anemia 
5,272 8.1% 767 8.3% 15,505 6.9% 
Alcohol Abuse 522 0.8% 71 0.8% 3,212 1.4% 
Drug Abuse 349 0.5% 51 0.5% 2,211 1.0% 
Psychoses 1,252 1.9% 163 1.8% 3,705 1.6% 
Depression 5,120 7.8% 751 8.1% 26,685 11.8% 
CHD 24,187 37.0% 3,252 35.0% 26,015 11.5% 
DVT 3,204 4.9% 442 4.8% 10,856 4.8% 
PE 1,346 2.1% 208 2.2% 4,481 2.0% 
AT 655 1.0% 92 1.0% 1,297 0.6% 
MI 4,696 7.2% 569 6.1% 5,335 2.4% 
Stomach CA 1,861 2.8% 245 2.6% 6,024 2.7% 
Pancreas CA 3,011 4.6% 466 5.0% 9,770 4.3% 
Brain CA 1,720 2.6% 272 2.9% 11,212 5.0% 
Lung CA 15,812 24.2% 2,047 22.0% 36,891 16.3% 
Kidney CA 6,308 9.6% 981 10.6% 19,799 8.8% 
Lymphomas 9,926 15.2% 1,507 16.2% 40,114 17.7% 
Leukemia 6,058 9.3% 948 10.2% 20,518 9.1% 
Myeloma 3,031 4.6% 476 5.1% 10,367 4.6% 
Colorectal CA 13,126 20.1% 1,817 19.6% 45,390 20.1% 
Gynecologic CA 5,755 8.8% 752 8.1% 34,106 15.1% 
CCI Charlson Comorbidity Index; CHF Congestive Heart Failure; CHD Coronary Heart 
Disease; DVT Deep vein Thrombosis; CA Cancer 
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Figure 2.1: CONSORT flow diagram. Flow diagram of the inclusion of patients from the 
national healthcare claims dataset. 
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The number of matched pairs post-propensity score matching were 39,989, 101,401 and 
27,319 for the statins- vs. non-statins-users comparison, statins vs. no treatment 
comparison and the non-statins vs. no treatment comparison, respectively. While 
baseline differences existed among treatment groups, matching provided samples that 
had minimal differences as all standardized scores were below 0.1  
 
Figure 2.2 displays the HR and associated 95% CI for the effect of treatment group on 
survival within the propensity-matched sample. Overall, there were no differences in 
survival between statin-users and non-statin-users. Among all cancers, statin-use prior 
to diagnosis improved overall survival compared to no treatment (HR 0.85, 95% CI 0.80-
0.91). When stratified by cancer type, this observation held true for lung cancer (HR 
0.88, 95% CI 0.78-0.98), renal cancer (HR 0.63, 95% CI 0.44-0.90) and leukemia (HR 
0.73, 0.58-0.92). Non-statin-use provided a similar reduction in overall survival 
compared to no treatment (HR 0.73, 95% CI 0.62-0.85); but when stratified, this held 
true only for pancreatic cancer (HR 0.53, 95% CI 0.29-0.98) and leukemia (HR 0.53, 
0.30-0.94).   
 
Dose intensity analysis determined that the effect observed is not dosage-dependent 
(Figure 2.3). By removing low-dosage statins and comparing to non-statins and non-
users, overall survival was of the same magnitude and direction observed in the overall 
analysis. The sensitivity analysis assessing age (Table 2.2) also showed no difference in 
effect within age groups when comparing statins to non-statins or non-statins to non-
users. However, patients under the age of 65 in the statins vs. non-users group had 
improved survival while those over the age of 65 did not. 
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Figure 2.2:  One-year survival analysis. Hazard ratios (HR) and associated 95% 
confidence intervals (CI) for the effect of treatment group on survival within the 
propensity-matched sample. Matching was conducted for each treatment group analysis. 
(*) signifies statistically significant result.  
 
 
ADAPTED FROM: El-Refai et al, JCO Clinical Cancer Informatics (2017) 
DOI:10.1200/CCI.17.99919 
 
43 
   
  
Figure 2.3: The effect of dose intensity on one-year survival. Statin exposure groups 
limited to medium and high dosages. The distribution of low, moderate and high dosage 
statins prior to matching is 7,918, 46,152 and 11,307, respectively. Hazard ratios (HR) 
and associated 95% confidence intervals (CI) for the effect of treatment group are 
presented. (*) signifies statistically significant result.  
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Table 2.2: Age sensitivity analysis for all exposure group analyses. Hazard ratios (HR) 
and associated 95% confidence intervals (CI) for the effect of treatment group are 
presented. 
  Statins Vs. Non-Statins Statins Vs. Non-
Users 
Non-Statins Vs. 
Non-Users 
Age HR 95% CI HR 95% CI HR 95% CI 
< 65 Yrs 0.67 0.40 1.10 0.71 0.55 0.92 0.79 0.54 1.17 
65-75 Yrs 1.17 0.92 1.48 0.94 0.84 1.05 0.93 0.72 1.20 
>75 Yrs 1.22 0.96 1.56 0.91 0.82 1.01 0.77 0.59 1.01 
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To examine differences among individual statins (Figure 2.4), we stratified molecules by 
natural and synthetic origin. Compared to simvastatin as reference, the more hydrophilic 
rosuvastatin (HR 1.21, 95% CI 1.03-1.43) and fluvastatin (HR 2.18, 95% CI 1.36-3.50) 
molecules were associated with a higher rate of death with no differences between other 
products, i.e. simvastatin is associated with a protective effect. When grouped by type, 
natural statins had a marginally protective effect on survival, but this was not statistically 
significant (HR=0.91, 95% CI 0.83-1.01)   
 
Bisphosphonate users (n=4,528) were compared to non-users and stratified by statin 
use. Among all cancers, bisphosphonates had a non-significant reduction in death when 
compared to non-users (HR 0.82, 95% CI 0.65-1.03) (Figure 2.5). Stratification by 
cancer type could not be completed due to limited population size. A treatment group 
consisting of patients using both statins and bisphosphonates (n=4,090) exhibited a 
much larger improvement in survival compared to a subset of non-users that did not 
receive either medication (HR 0.60, 95% CI 0.45-0.81). 
 
The majority of subjects remained on statin therapy with an average of 78.3% of days in 
the post-index period covered by statin therapy and only 19 out of 65,440 patients 
stopped statin therapy after cancer diagnosis. More than half of this treatment group 
received statins for the entire follow-up period. Generally, we observed that the statin 
cohort continued on statin therapy for the majority of their post-diagnosis follow-up time. 
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Figure 2.4:  The effect of statin stratification by type and class on one-year survival. In 
comparison by type, simvastatin was used as reference. In comparison by class, 
synthetic statins were used as reference. The list of natural statins included lovastatin, 
pravastatin and simvastatin. Synthetic statins included rosuvastatin, atorvastatin, 
fluvastatin and pitavastatin. Hazard ratios (HR) and associated 95% confidence intervals 
(CI) for the effect of treatment group are presented.  
 
 
 
 
 
 
 
 
 
 
N HR
Simvastatin 28,714 Ref Ref Ref
Lovastatin 3,935 0.97 0.77 1.21
Pravastatin 7,307 1.01 0.85 1.19
Rosuvastatin 6,492 1.21 1.03 1.43
Atorvastatin 18,443 1.04 0.92 1.17
Fluvastatin 372 2.18 1.36 3.50
Pitavastatin 112 0.41 0.06 2.91
Synthetics 25,419 Ref Ref Ref
Natural 39,956 0.91 0.83 1.01
95% CI
0 .1 1 1 0
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Figure 2.5:  The effect of synergistic statin combinations on one-year survival. 
Bisphosphonates assessed in the analysis were alendronate sodium, etidronate 
disodium, ibandronate sodium, pamidronate disodium, risedronate sodium and 
zoledronic acid. Bisphosphonates and dipyridamole users were required to have at least 
a 90 cumulative days supplied in the 6 months prior to cancer diagnosis. Hazard ratios 
(HR) and associated 95% confidence intervals (CI) for the effect of treatment group are 
presented. (*) signifies statistically significant result.  
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D. DISCUSSION 
 
This observational cohort study used epidemiological data and identified a significant 
effect on the overall survival of cancer patients who receive statins at the time of 
diagnosis. This advantage was specific to cancers of the lung, kidney, and leukemias. In 
addition, the concurrent use of a bisphosphonate with a statin was associated with an 
improvement in overall survival, but stratification by cancer type was not possible due to 
the small sample size. This observation is consistent with the mechanisms of action of 
the two agents suggesting the theoretical potential for synergy in a prospective study. 
The effect of dipyridamole in combination with statin was not significant in the small 
cohort of patients receiving this combination (n=651). The effect of statins was 
comparable to other cholesterol-lowering medications, which is consistent with a recent 
cohort study in postmenopausal women showing that regular use of statins or other-lipid-
lowering medications was associated with decreased cancer death (111). Multiple 
systems or pathways may explain the mechanism by which statins induce their effect on 
cancer survival including inhibition of Ras, improvement of immune surveillance, and the 
reduction of venous thromboembolisms (VTE). 
 
Statins impact normal cell survival mechanisms including cell proliferation, pro-apoptotic 
effects, induction of autophagy, and anti-invasive and anti-migration effects that have 
been systematically studied in in vitro and in vivo models systems. The overarching 
hypothesis is the potential effect of statins on the Ras signaling pathway (163-169). Lung 
cancer, pancreatic cancer and hematopoietic/lymphoid cancers are associated with high 
rates of K-Ras mutation (38%, 63% and 21%, respectively) (170). High frequency of 
mutation may explain why patients with these cancers benefited in our analysis. 
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However, our results did not show an effect in colorectal cancer, which also has a high 
frequency in K-Ras mutation (170). Stain-use following diagnosis was previously shown 
to reduce colorectal cancer–specific mortality (119) and the prospective use of 
simvastatin with cetuximab/irinotecan in K-Ras mutant patients had favorable disease 
control rate (129). Considering in vitro evidence, statin-mediated modulation of protein 
prenylation in cancer cells requires suprapharmacologic concentrations (e.g., 1-25µM) 
for prolonged periods (171-174). Previous studies from our group demonstrated high 
(7.5mg/kg b.i.d.) simvastatin doses, ~25-fold of the typical daily dose (i.e., 40mg), 
achieved maximum plasma concentrations that were in the range of 0.08-2.2µM (175). 
Consistent with this, our results show that the dose-intensity of typical dosages 
cholesterol lowering treatment does not impact overall survival, suggesting other 
mechanisms may be involved.  
 
Prior studies have suggested the immuno-stimulatory effects of statins as the 
mechanism for anti-cancer activity. By inhibiting the mevalonate pathway, statins can 
induce innate lymphocyte activation and increase immune surveillance. Depletion of 
prenyl pyrophosphates in human dendritic cells generates danger signals that can 
translate into caspase-1 activation. Caspase-1 cleaves interleukin-1-beta (IL-1β) and IL-
18 into their activated forms allowing the release of cytokines that include interferon-γ 
and IL-2 (176). Statin-induced activation of IL-2 primed γδ T cells and natural killer cells 
exhibit potent antitumor cytotoxicity and ectopic GGPP reintroduced into the cell culture 
abolishes this effect (177, 178). Immunomodulation may be an important contributor as 
immune cells are more likely to be exposed to higher statin concentrations than cancer 
cells. 
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Finally, given the lack of difference between statin and non-statin drugs, the survival 
effect may in part be due to reductions in thrombotic events. Observational studies show 
that statins lower the risk of VTE in the cancer population, thereby increasing OS (179). 
In a prospective observational cohort of 1,434 cancer patients, VTEs occurred in 2.94% 
of patients at 12 months and 3.54% at 24 months for statin users. In comparison, those 
who were not treated with statins had elevated rates of VTE of 7.13% at 12 months and 
8.13% at 24 months (P= 0.04). Among newly-diagnosed cancer patients who were 
prospectively followed for a two-year period, statins users had a lower risk of VTE than 
non-users (HR 0.43, CI 0.19 to 0.98). In contrast, a meta-analysis of 27 trials assessing 
the effect of statin use and the lowering of LDL cholesterol on cancer incidence and 
mortality found a lack of effect after a median of five years of therapy, but a small effect 
within the first year after diagnosis (180). In the ACALM study, hyperlipidemia was 
associated with a significantly reduced mortality rate in lung, breast, prostate and bowel 
cancers (181). With respect to age, our analyses shows that those over 65 had no 
significant benefit from statin treatment, which may be the result of an overall increased 
VTE risk in that population. More work is needed to understand how cholesterol lowering 
medications impact the risk of thrombotic events in cancer and whether this effect 
explains part of the overall protective effect observed in this study.  
 
This study is subject to the limitations of all claims-based studies (182, 183). Claims data 
lack detailed information on laboratory values or tumor staging, which may have 
influenced the outcomes of this study. This study was limited to a one-year follow-up due 
to the availability of data and the heterogeneity and time-varying confounded with longer 
follow-up. Lastly, while propensity score matching is known to reduce selection bias in 
non-randomized studies, it is possible that residual bias is present or that unmeasured 
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confounders may have impacted these findings (158). This study is strengthened by a 
large sample size, inclusion of minimum medication exposure criteria (e.g. 90 days 
supplied), and by inclusion of an active control group, which are often lacking in similar 
studies. 
 
E. CONCLUSION 
 
Epidemiological health outcomes data can be used to test hypotheses based on the 
effect of drugs on specific biological pathways and processes. Our work shows that the 
use of statins alone and in combination with bisphosphonates could provide a survival 
benefit in certain cancers. We have shown the applicability of health outcomes research 
in the assessment of response dependent on differing exposure groups. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © Sherif M. El-Refai 2017
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CHAPTER 3  
A. OVERVIEW 
 
Immune checkpoint inhibitors (ICI) are designed to restore a patient’s antitumor immune 
response, which has been attenuated during the process of tumor development. Antigen 
presenting cells (APC) normally express programmed death ligand 1 (PD-L1) that, when 
bound by PD-1 on T cells, signal an exhausted active immune response. In cancers that 
express PD-L1 on tumor cells, PD-1 receptor expressed on T cells, B cells, and NK cells 
of an activated immune system, and the interaction of PD-1 and PD-L1 characterize an 
adaptive and immune-evasive response by the tumor. This immune-evasive interaction 
can be reversed by addition of ICIs that inhibit either molecule (53).  Recently, agents 
that modulate the tumor immune response have provided durable clinical benefit to 
patients with late-stage or recurrent disease. Nivolumab (Opdivo®) has received FDA 
approval for the treatment of squamous and non-squamous metastatic non–small cell 
lung cancer (NSCLC) and metastatic renal cell carcinoma with progression on or after 
chemotherapy (184). Nivolumab is a human IgG4 antibody that blocks programmed 
death 1 (PD-1) receptor and potentiates activation of T cells (185). Nivolumab therapy 
demonstrated improved tumor-related outcomes in multiple types of cancer (186). 
Pembrolizumab (Keytruda®), another PD-1 inhibitor, received FDA approval to treat 
advanced (metastatic) NSCLC whose disease has progressed after other treatments 
and with tumors that have 50% programed death  ligand 1 (PD-L1) expression (187). 
PD-1 inhibition facilitates activation of potentially autoreactive T cells, leading to 
inflammatory adverse events across a range of tissues. Patients with a history of 
autoimmune diseases were excluded from clinical trials of PD-1 inhibitors (188). 
Exclusions included multiple sclerosis, autoimmune neuropathy, Guillain-Barre 
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syndrome, myasthenia gravis, systemic lupus erythematosus, connective tissue 
diseases, scleroderma, inflammatory bowel disease, Crohn’s disease, ulcerative colitis, 
and hepatitis. Patients with rheumatoid arthritis, Sjogren’s syndrome, and psoriasis were 
included if disease was well-controlled. Although these therapies hold great promise, 
ICIs can trigger a variety of immune-related adverse events (irAEs). These include 
dermatologic, gastrointestinal, hepatic, endocrine, and other inflammatory conditions and 
they are believed to result from general immune response enhancement (189).  Khan et 
al have shown a relatively high rate of autoimmune diseases, approximately 14%, 
among lung cancer patients, and these patients were more likely to be older females 
(190). The objective of this study was to confirm findings of Khan and colleagues in a 
more diverse cohort and identify whether cancer patients with autoimmune disease 
exhibit different baseline characteristics and comorbidities. 
 
B. METHODS 
 
We identified lung and renal cancer patients using Truven Health MarketScan 
Commercial Claims and Medicare Supplemental Database. The Marketscan database 
includes approximately 40 million individuals from over 160 large employers and health 
plans across the US and includes healthcare claims with diagnosis and procedure codes 
for medical encounters and all prescription medication fills. These data are de-identified 
in compliance with the Health Insurance Portability and Accountability Act regulations 
(HIPAA) and the University of Kentucky Institutional Review Board approved the use of 
the database for this study. 
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Adults 18 years and older diagnosed with cancer between January 1, 2010 and 
November 31, 2013 were identified. At least 2 inpatient or outpatient diagnoses 
separated by at least 14 days were required and the date of the first qualifying diagnosis 
of cancer was defined as the index date. We directed our analyses to only lung and 
renal cancer due to the initial approvals of the immune checkpoint inhibitor, nivolumab. 
Nivolumab received approval for the treatment of metastatic non-small cell lung cancer 
on March 4, 2015 and for metastatic renal cell carcinoma on November 23, 2015. 
Patients were required to have at least 12 months of pre-index and a minimum of one-
month post-index continuous enrollment in the database.  We assessed patients for 
diagnosis of autoimmune diseases prior to or after diagnosis of cancer using ICD-9 
codes for 41 autoimmune diseases. It is necessary to assess autoimmune disease 
before and after diagnosis because newly diagnosed autoimmune conditions would still 
have bearing on therapeutic decision-making practices. Prevalence was determined by 
the presence of 2 or more claims to autoimmune diseases separated by at least 30 
days. Baseline characteristics and Elixhauser and Charlson comorbidity indexes of 
patients with and without autoimmune diseases were compared. These indexes include 
17 and 31 categories of comorbid conditions, respectively, and have been widely used 
for risk adjustment with health outcomes data (154, 155). Two sample t-test and chi-
square tests were conducted to assess significant differences between groups. 
Bonferroni correction was applied due to multiple comparisons. 
 
C. RESULTS 
 
We identified 53,783 lung cancer patients and 27,349 renal cancer patients of whom 
13,156 (24.5%) and 8,217 (30.1%) also had an autoimmune disease, respectively. 
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Hypothyroidism (55.8%, 56.7%), rheumatoid arthritis (20.2%, 18.1%) and type 1 
diabetes mellitus (11.5%, 14.5%) were the most common for both lung and renal cancer 
patients respectively (Table 3.1). Baseline characteristics and comorbidities are listed in 
Table 3.2. Cancer patients with autoimmune disease were more likely to be female, 
older and had higher prevalence of comorbidities than cancer patients without 
autoimmune disease (Table 3.2).  
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Table 3.1: Autoimmune (AI) disorders in lung and renal cancer patients between the 
years 2009-2013. 
Autoimmune Disorder 
Among Lung CA 
Patients with AI 
Disease. N (%) 
Among Renal CA 
Patients with AI 
Disease. N (%) 
Rheumatoid Arthritis 2,653 (20.2) 1490 (18.1) 
Psoriasis 527 (4.0) 402 (4.9) 
Systemic Lupus Erythematous 225 (1.7) 120 (1.5) 
Systemic Sclerosis 78 (0.6) 20 (0.2) 
Sicca Syndrome 115 (0.9) 70 (0.9) 
Autoimmune NOS 37 (0.3) 20 (0.2) 
Autoimmune Hepatitis 59 (0.5) 72 (0.9) 
Primary Biliary Cirrhosis 38 (0.3) 33 (0.4) 
Celiac Disease 71 (0.5) 51 (0.6) 
Ankylosing Spondylitis 506 (3.9) 402 (4.9) 
Polymyalgia Rheumatica 227 (1.7) 141 (1.7) 
Addison's Disease 357 (2.7) 196 (2.4) 
Ulcerative Colitis 352 (2.7) 238 (2.9) 
Crohn's Disease  258 (2.0) 208 (2.5) 
Meniere's Disease 89 (0.7) 67 (0.8) 
Hashimoto's Disease 89 (0.7) 67 (0.8) 
Polyartheritis Nodosa 174 (1.3) 89 (1.1) 
Giant Cell Arthritis 93 (0.7) 45 (0.6) 
Pernicious Anemis 710 (5.4) 301 (3.7) 
Autoimmune Hemolytic Anemia 39 (0.3) 22 (0.3) 
Idiopathic Thrombocytopenic Purpura 152 (1.2) 82 (1.0) 
Thyrotoxicosis 157 (1.2) 100 (1.2) 
Multiple Sclerosis 200 (1.5) 103 (1.3) 
Iridocyclitis 280 (2.1) 209 (2.5) 
Pemphigus 32 (0.2) 33 (0.4) 
Eczema 312 (2.4) 288 (3.5) 
Alopecia Areata 34 (0.3) 26 (0.3) 
Vitiligo 18 (0.1) 29 (0.4) 
Wegener's Granulomatosis 28 (0.2) 21 (0.3) 
Dermatopolymyositis 33 (0.3) 10 (0.1) 
Myasthenia Gravis 89 (0.7) 58 (0.7) 
Scleroderma 62 (0.5) 47 (0.6) 
Antiphospholipid 3 (0.0) 5 (0.1) 
Guillian-Barre Syndrome 28 (0.2) 23 (0.3) 
Type 1 Diabetes Mellitus 1,507 (11.5) 1,189 (14.5) 
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Hypothyroidism 7,334 (55.8) 4661 (56.7) 
Hyperthyroidism 157 (1.2) 100 (1.2) 
Sweet's Syndrome 215 (1.6) 183 (2.2) 
Sjogren's Syndrome 115 (0.9 70 (0.9) 
Pyoderma Gangrenosum 7 (0.1) 1 (0.0) 
Sarcoidosis 249 (1.9) 129 (1.6) 
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Table 3.2:  Baseline characteristics and comorbidities between lung and renal cancer 
patients with or without autoimmune disease. 
  
Cancer W/ 
Autoimmune 
Cancer W/O 
Autoimmune   
  N (21,373) % N (59,759) % P Value 
Age Categories           
< 65 Yrs 8,393 39.3 25,672 43.0 <.0001 
65 to 74 Yrs 6,439 30.1 16,762 28.1 <.0001 
75 to 80 Yrs 3,545 16.6 9,276 15.5 <.0001 
>80 Yrs 2,996 14.0 8,049 13.5 <.0001 
Gender (F) 12,133 56.8 25,140 42.1 <.0001 
CHF 2,938 13.8 6,860 11.5 <.0001 
Arrhythmias 5,530 25.4 13,659 22.9 <.0001 
Valvular disease 2,986 14.0 6,920 11.6 <.0001 
Pulmonary Circulation 1,150 5.4 2,953 4.9 0.0119 
Peripheral Vascular 5,812 27.2 14,187 23.7 <.0001 
Hypertension 
uncomplicated 13,814 64.6 35,614 59.6 <.0001 
Hypertension complicated 2,375 11.1 5,067 8.5 <.0001 
Paralysis 211 1.0 584 1.0 0.899 
Other neurological 1,919 9.0 4,231 7.1 <.0001 
Chronic pulmonary 9,063 42.4 25,053 41.9 0.2219 
Renal failure 3,085 14.4 6,130 10.3 <0.0001 
Liver disease 2,528 11.8 6,767 11.3 0.047 
Peptic ulcer disease 308 1.4 772 1.3 0.1032 
HIV/AIDS 33 0.2 116 0.2 0.2445 
Metastatic Cancer 4,340 20.3 15,952 26.7 <.0001 
Coagulopathy 1,145 5.4 2,332 3.9 <.0001 
Obesity 1,598 7.5 3,402 5.7 <.0001 
Weight Loss 1,599 7.5 4,778 8.0 0.0165 
Fluids and Electrolytes 3,549 16.6 8,679 14.5 <.0001 
Blood Loss Anemia 990 4.6 2,075 3.5 <.0001 
Deficiency Anemia 1,358 6.4 2,835 4.7 <.0001 
Alcohol Abuse 278 1.3 1,087 1.8 <.0001 
Drug Abuse 246 1.2 624 1.0 0.1933 
Psychoses 397 1.9 1,148 1.9 0.5595 
Depression 2,713 12.7 5,888 9.9 <.0001 
CHD 5,791 27.1 14,702 24.6 <.0001 
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More than a quarter of patients diagnosed with lung and renal cancer were found to 
have a comorbid autoimmune condition. When considering that immune checkpoint 
inhibition is only approved in late stages of cancer, it is not clear whether the benefits of 
pursuing treatment in patients with autoimmune disease outweigh the risk of inducing 
worse irAEs. Several case reports have been published showing that while 
discontinuation of the immune checkpoint inhibitor results in resolution of the irAE, long 
courses of medications specific to the autoimmune reaction may be needed to mitigate 
the effects of ICI therapy (191-193). In a large systematic review of 251 cases involving 
anti-CTLA-4 and anti-PD-1 agents, approximately 52% of treated patients discontinued 
ICI therapy due to the irAEs.(191) Less than 10% required no treatment for the irAE, 
while the remainder was treated with corticosteroids, infliximab (an anti-tumor necrosis 
factor (TNF) agent), or disease-modifying anti-rheumatic drugs (DMARDs). Death due to 
the irAEs occurred in 4.7% of patients. Cutaneous autoimmune reactions are commonly 
associated with ICI therapy, but a case report on two patients with metastatic melanoma 
illustrated that irAEs may not appear until long after initiation of therapy.(193) An autopsy 
study presented an elderly melanoma patient exhibiting a systemic inflammatory 
response that affected multiple organ sites ultimately resulting in the death of the patient 
(194). 
 
This study is subject to the limitations of all claims-based studies (182, 183). Notably, 
claims data lack detailed information on laboratory values or information on tumor 
staging, which may have influenced the outcomes of this study. This study was limited to 
a one-year follow-up due to the availability of data and the heterogeneity and time-
varying confounded with longer follow-up. This study is strengthened by a large sample 
size and the inclusion of both commercial and medicare claims. 
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D. CONCLUSION 
 
The exclusion of patients with autoimmune conditions from the approval studies of 
nivolumab and pembrolizumab resulted in a lack of clinical guidance for a large 
population of patients that oncologists must decide whether to treat or not. In late stage 
treatment of these cancers, the potential durable response associated with immune 
checkpoint inhibitors will need to be weighed against the worsening of the patient’s 
autoimmune condition, a decision for which clinical trials have not provided a concrete 
answer. Future evaluation of real-world treatment patterns will be needed to assess ICI 
usage and response in patients with autoimmune conditions.  
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CHAPTER 4  
A. OVERVIEW 
 
Immune checkpoint inhibitors (ICI) are designed to restore a patient’s antitumor immune 
response, which has been attenuated during the process of tumor development. Antigen 
presenting cells (APC) normally express programmed death ligand 1 (PD-L1) that, when 
bound by programmed death 1 receptor (PD-1) on T cells, signal an exhausted active 
immune response. In cancers that express PD-L1 on tumor cells, PD-1 receptor 
expressed on T cells, B cells, and NK cells of an activated immune system, and the 
interaction of PD-1 and PD-L1 characterize an adaptive and immune-evasive response 
by the tumor. Cytotoxic T lymphocyte-associated molecule-4 (CTLA-4) is a homolog to 
CD28 and competitively binds to B7 on antigen-presenting cells providing a co-inhibitory 
signal, preventing the priming and activation of CD8+ T cells (195). These immune-
evasive interactions can be reversed by addition of ICIs (53). These agents that 
modulate the tumor immune response have recently provided durable clinical benefit to 
patients with late-stage or recurrent disease.  
 
To date, nivolumab (Opdivo®) has received FDA approvals for the treatment of 
squamous and non-squamous metastatic non–small cell lung cancer (NSCLC), 
metastatic renal cell carcinoma, advanced melanoma, Hodgkin lymphoma, previously 
treated locally advanced or metastatic urothelial carcinoma, hepatocellular carcinoma 
patients previously treated with sorafenib and microsatellite instability-high (MSI-H) or 
mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) that has 
progressed following treatment with a fluoropyrimidine, oxaliplatin and irinotecan (184, 
186). Nivolumab is a human IgG4 antibody that blocks PD-1 and potentiates activation 
 62 
   
  
of T cells (185). Pembrolizumab (Keytruda®), also a PD-1 inhibitor, received FDA 
approval for the treatment of advanced (metastatic) NSCLC that has progressed after 
other treatments and for tumors with at least 50% expression of programmed death 
ligand 1 (PD-L1) by tumor cells. Specifically, advanced melanoma, metastatic head and 
neck squamous cell carcinoma, classical Hodgkin lymphoma, advance or metastatic 
urothelial carcinoma, gastroesophageal junction cancer whose tumors express PD-L1, 
and metastatic solid tumors that are MSI-H or dMMR are eligible for this therapy (187). 
 
The only approved biomarker of response for any ICI is measurement of PD-L1 
expression from the tumor. The Keynote-001 trial sought to correlate response to MK-
3475, a PD-1 inhibitor, with expression of PD-L1. In the melanoma arm, PD-L1 
expression on tumor cells increased the response rate in 49% compared with 13% of 
PD-L1 negative patients. The NSCLC arm of this study showed that when greater than 
50% of tumor cells expressed PD-L1, response to MK-3475 was predicted and this was 
observed in nearly 25% patients. For all patients, response rate to MK-3475 was about 
19%, irrespective of PD-L1 expression in the tumor. Median progression free survival 
(PFS) was 14.1 months in PD-L1 strongly positive patients compared with 9.3 months in 
the weakly positive population (56). These findings preclude PD-L1 expression from 
being an exclusionary predictive biomarker. The limitations of this assay include timing 
of tissue acquisition, tumor heterogeneity, and timing of therapy relative to the 
expression of PD-L1 suggesting that finding a more robust biomarker of response is 
needed.  
 
Applying precision medicine principles to immuno-oncology requires the discovery of 
biomarkers that can identify the patients most likely to benefit from this class of 
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treatment. Robust biomarkers need to encompass an efficient, repeatable and easily 
accessible source of biological data from the patient. Determination of PD-L1 expression 
requires direct sampling of tumor tissue from a patient which necessitates an invasive 
procedure. If samples banked early during treatment and then used later to determine 
expression levels, the assayed expression levels may not represent the tumor or 
metastases in the current state. Predictive biomarkers that can be measured from 
peripheral blood sampling allow the inclusion of this tool into clinical practice with 
minimal workup, allow for assay immediately prior to initiation of ICI treatment, and can 
be repeated throughout therapy for monitoring purposes. I sought to determine whether 
peripheral factors associated with the patient’s immune response or malignancy that 
have the precision and robustness to be more predictive than PD-L1 expression for 
anticipating response to PD-1 inhibitor therapy.  
 
Several comorbid conditions have been associated with the development and 
progression of cancer but the long-term effect on the immune system may also impact 
response to ICI treatment (196). It is estimated that potentially 25% of all malignancies 
develop after exposure to chronic inflammation and to viral and bacterial infections that 
initiate an immune response (197). Chronic inflammation encompasses multiple 
conditions. Metabolic syndrome, one family of chronic inflammatory diseases, has 
consistently been correlated with the development of several tumor types. Worldwide 
there are over 312 million people with a BMI>30 kg/m2 and within the last four decades, 
the prevalence of obesity has amassed to approximately 50% of adults within the US 
(198). Obese patients develop more localized tumors, have earlier relapse, and a 
diminished overall survival (199). Hyperlipidemia includes low high-density-lipoprotein 
(HDL) cholesterol and elevated low-density lipoprotein (LDL) cholesterol. Low HDL and 
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high serum levels of total cholesterol have been associated with higher incidence of 
lung, prostate and post-menopausal breast cancer (200, 201). This study followed over 1 
million patients for 16 years who had no reported history of cancer and identified that, 
independent of high body mass, type 2 diabetes mellitus (T2DM) is a predictor of 
mortality in pancreatic, breast, liver and bladder cancer (202). The potential causal link 
between metabolic syndrome, inflammation and cancer is adipose tissue hypoxemia 
(203). This phenotype is characterized by inflammatory cytokines in plasma and the 
adipose tissue itself as well as macrophage infiltration and activation.  
 
Immune cells secrete specific cytokines and chemokines that act as survival and 
proliferation factors for the promotion of malignant tumor cells. The presence of 
inflammation and the secretion of inflammatory mediators can lead to the induction of 
transcription factors such as NF-κβ. In the initial phase of tumor development, 
inflammatory mediators such as cytokines, reactive oxygen species (ROS), and reactive 
nitrogen species (RNS) derived from tumor-infiltrating immune cells induce epigenetic 
alterations in pre-malignant lesions and silence tumor suppressor genes (204). 
Accumulation of microbial pathogens and tissue necrosis activate transcription factors 
that are necessary for the expression of pro-angiogenic factors (IL-8, VEGF), growth 
factors (IL-6, GM-CSF), anti-apoptotic factors (Bcl-XL, c-FLIP), invasion-promoting 
factors (MMP-2, MMP-7, MMP-9, uPA), inflammatory enzymes (PGHS-2, LOX), 
prostaglandins, iNOS, chemokines (CCL2, CCL20, IL-8), and pro-inflammatory cytokines 
(IL-1, IL-6, IL-23, TNF, TGF-β, EGF) that support the malignant phenotype (205). Of the 
cytokines released, transforming growth factor beta (TGF-β) and tumor necrosis factor 
alpha (TNF-α) help activated NF- κβ in a process called epithelial-mesenchymal 
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transition (EMT). EMT is a process necessary for tumor invasiveness and metastasis to 
other sites (206). 
 
While we understand that a pro-inflammatory cytokine-rich environment promotes the 
formation of some tumor types, we are interested in understanding whether these 
cytokines induce adaptive immune resistance in lung cancers. If true, patients with an 
inflammatory cytokine-rich periphery may respond well to certain immune checkpoint 
inhibitors. Importantly, PD-L1 expression is induced by interferon (IFN) activity, and 
indirectly by IL12, in both endothelial and breast cancer cells (207, 208). Further, Taube 
and colleagues investigated the signaling events that induce PD-L1 expression and 
demonstrated that many cytokines were overexpressed expression in melanoma cell 
lines, including RANTES, CXCL1, IL10, IL18 and IL21. In vitro stimulation of melanoma 
cells by IFN-γ induced PD-L1, but recombinant forms of the other cytokines failed to 
increase cell surface expression of PD-L1 with or without IFN-γ (54). In a separate study, 
incubation of activated T-cells with IL10 (+/- IFN-γ) induced expression of PD-L1 on 
monocytes thereby reducing T-cell activation (51). Increased expression of these 
molecules correlates with increased T cell infiltration (209, 210). Because PD-L1 
expression is modulated by the interferons (α, β, and γ) in a dose- and time-dependent 
manner as measured by both mRNA and cell surface expression, regulation of this 
molecule is important for maintaining control of the immune response and is dependent 
on peripheral cytokines (207).  
 
Inflammatory diseases are, in part, caused by poor lifestyle choices and can contribute 
to cancer development. Paradoxically, the presence of inflammatory diseases may serve 
as biomarkers of durable response to immune checkpoint inhibitors. Given these 
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studies, there is a fundamental gap in understanding of the timing of expression of PD-
L1 in NSCLC tumors and PBMC and how those levels relate to the state of the 
inflammatory response and response to ICI. To measure the relationship between 
chronic inflammation and the response to ICIs, we investigated the following two aims: 
• Retrospective analysis of local Markey Cancer Center (MCC) data for a history 
of chronic inflammation and correlate with response to nivolumab therapy in 
NSCLC patients 
• Assess national healthcare claims data to determine if ICI-treated patients with a 
history of chronic inflammation exhibited improved overall survival 
Health outcomes research is a methodology used to identify and measure the link 
between treatments or interventions and the desired outcome of interest. With the 
limited, real-time clinical applicability of basic science research and the constraints of 
expensive, time-consuming and limited populations of clinical trials, health outcomes 
data research bridges the gap to identify the most effective intervention. Health 
outcomes research can be used to identify disparities among different populations and 
further patient-centered outcomes. Advances in bioinformatics using a “Big Data” 
approach provide an opportunity for novel insights regarding the discovery of biomarkers 
of response (211). Researcher are now able to use real-world data to conduct high 
quality investigations that demonstrate the value of this novel class of treatment and the 
variables that influence its success. The combination of epidemiological evidence and 
preclinical data will provide strong rationale for future prospective clinical studies.  
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B. METHODS 
 
Retrospective Study Subjects and Methods 
Metastatic NSCLC-diagnosed patients treated at the MCC with nivolumab were 
retrospectively identified between March 2015 and February 2016 using an institutional 
IRB-approved study. The study was deemed as minimal risk and was exempt from 
obtaining informed consent from study patients. The range of dates chosen covered the 
span of time from the FDA approval of nivolumab treatment for patients diagnosed with 
metastatic NSCLC with progression on or after platinum-based chemotherapy in NSCLC 
to the date this study was conducted. The data were gathered by reviewing electronic 
medical records. Data collected included gender, age, comorbid condition history, 
previous chemotherapy treatment, nivolumab treatment start date and number of cycles 
of therapy completed. Cycles of nivolumab therapy received were utilized as a surrogate 
for response. Patients treated with 6 cycles or more of therapy were considered to have 
a robust, objective response. Chronic inflammatory conditions collected included the 
diagnosis of hyperlipidemia, hypertension, diabetes mellitus, obesity or chronic 
obstructive pulmonary disorder (COPD). No statistical analyses or power calculations 
was undertaken.  
Tumor Acquisition & PD-L1 Expression 
Using the identified patients treated with nivolumab, the MCC Biospecimen and Tissue 
Procurement Shared Resource Facility was used as an honest-broker to query for 
formalin-fixed, paraffin-embedded (FFPE) tumor tissue samples associated with each 
patient. Of the 45 patients for which health history was collected, PD-L1 expression was 
assessed for each tumor sample retrieved. The PD-L1 IHC 28-8 pharmDx assay is 
approved by the US Food and Drug Administration (FDA) as a complementary 
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diagnostic for non-squamous NSCLC and melanoma in the USA (212). The rabbit 
monoclonal antihuman PD-L1 antibody 28-8 was produced by Abcam (San Francisco, 
CA, USA). The 28-8 antibody was tested using Dako PD-L1 IHC 28-8 pharmDx (Dako 
North America; SK005) and the Dako-recommended protocol, as previously described 
(213). Tumor tissue sections were de-paraffinized and antigen-retrieval was initiated at 
97 °C for 20 min. Detection of PD-L1 protein was conducted using 2 µg/mL of the 
antibody on the Autostainer Link 48 according to Dako instructions. Upon completion, 
the stained sample slides were sent to Kimberly Abshear M.D. of UK Pathology to 
measure the expression level of PD-L1 and to determine the histology as either 
squamous or non-squamous carcinoma. 
Outcomes Study Subjects 
For the health outcomes research aim of this study, the Truven Health MarketScan 
Commercial Claims and Medicare Supplemental Databases was used to complete the 
outcomes aim of this study. The Marketscan database includes approximately 40 million 
individuals from over 160 large employers and health plans across the United States and 
includes healthcare claims with diagnosis and procedure codes for medical encounters 
and all prescription medication fills. Data are de-identified in compliance with the Health 
Insurance Portability and Accountability Act regulations (HIPAA), and the University of 
Kentucky Institutional Review Board previously provided blanket approval the use of the 
database for studies conducted by UK researchers. Adults aged 18 years and older 
treated with an ICI between January 1, 2013 and December 31, 2015 were identified 
using J codes associated with the medications. The healthcare common procedure 
coding system (HCPCS) is a standardized coding system, including current procedural 
terminology (CPT) codes and J codes, which is used to identify products, supplies or 
services. Patients were required to have at least 24 months of pre-index and a minimum 
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of one-month post-index continuous enrollment in the database (Figure 4.1). Patients 
were diagnosed with one of the following types of cancer as categorized using the 
international classification of diseases, ninth revision (ICD-9) codes: Lung cancer (162.2 
– 162.9) or Melanoma (172.0-172.9) (214). The ICIs included were nivolumab (C9453, 
J9299), pembrolizumab (C9027, J9271), and ipilimumab (J9228). At least two inpatient 
or outpatient diagnoses within 14 days were required, and the date of the first qualifying 
diagnosis of cancer was defined as the index date. Exposure groups were defined as: 
ICI-treated patients with a history of chronic inflammatory conditions or ICI-treated 
patients without a history of chronic inflammatory conditions. Chronic inflammatory 
conditions included the diagnosis of hyperlipidemia, hypertension, obesity, diabetes 
mellitus or chronic obstructive pulmonary disorder (COPD).  
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Figure 4.1:  Health outcomes data analysis timeline and process. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Pre-Index 12-Months Post-Index 
24-Month Pre-
Index 
ICI-Treated 
Population 
(All Cancers) 
Stratify by Chronic Inflammatory Condition, 
Propensity-score matching with CCI & 
Previous Therapies 
Outcomes Analysis – Overall 
Survival 
Truven claims data stratification and analysis approach. An illustration 
representing the manner in which the desired patient population was identified 
under Truven and how the relationship between chronic inflammatory 
conditions and ICIs are assessed. 
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Outcomes Data Measures & Statistical Methods 
Patient demographic characteristics included age, gender, geographic region and urban 
residence. Clinical characteristics measured during the 24-month pre-index period 
included previous chemotherapy treatments, previous radiation exposure, and the 
Charlson Comorbidity Index (CCI) (154).  CCI includes 17 categories of comorbid 
conditions, respectively, and are widely used for risk adjustment with health outcomes 
data. Presence of metastatic disease was assessed on the index date. The outcome of 
interest is one-year overall survival. Pairwise analyses were carried out between the two 
exposure groups: ICI-treated patients with a history of a chronic inflammatory disorders 
versus ICI-treated patients without a history of chronic inflammatory disorders. 
Propensity score matching was conducted using baseline comorbidities, medications, 
and demographic information to achieve balance between treatment groups. Propensity 
scoring mimics the randomization process of a clinical trial so that each matched pair 
has the same baseline probability to receive either treatment (156-158). Matched pairs 
should be similar in all baseline characteristics. Patients with the same cancer type were 
matched using a greedy, nearest neighbor algorithm with a caliper set at 0.2 times the 
standard deviation of the propensity scores in the sample, allowing for up to five 
matches for each treated person (159). Standardized differences were calculated. A 
standardized difference of <0.10 is generally considered to be non-significant (160).  To 
address any residual confounding after propensity score matching, covariates were also 
incorporated in the final regression models (157). The final model included the following 
adjustment covariates: age, CCI score, gender, region, urban, myocardial infarction, 
congestive heart failure, peripheral vascular disease, cerebrovascular disease, 
chemotherapy and radiation.  
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Cox proportional hazard regression models, accounting for correlation within matched 
pairs, were used to assess risk of death within one year of diagnosis among all cancers 
and then stratified among each cancer. Follow-up was terminated for those surviving 
beyond one year and were censored. Hazard ratios (HR) and 95% confidence intervals 
(CI) are reported. A p-value of <0.05 is considered statistically significant. All matching 
and statistical analyses were conducted in SAS. 
 
C. RESULTS 
 
Identification of chronic inflammatory diseases as precursor to response in MCC 
patients 
We identified 45 patients diagnosed with metastatic NSCLC treated with nivolumab 
between the dates of March 2015 and February 2016. The average number of cycles of 
nivolumab therapy administered for all 45 patients is 5.49 with a standard deviation of 
5.03 (Figure 4.2). Nine patients achieved long-term objective response (Mean=8.5 
cycles, SD=1.2), representing 20% of the patient population. Consistent with prior 
studies, approximately 20% of treated patients achieved an objective response/clinical 
benefit (> 6 cycles of nivolumab) in the absence of molecular selection for therapy (47, 
215). Of the 45 patients, twenty-nine had at least one, pre-existing, comorbid, chronic 
inflammatory condition. Eleven patients had two or more chronic inflammatory 
conditions. Patients with no history of chronic inflammatory conditions averaged 3.88 
cycles of nivolumab treatment (SD = 0.28), those with at least one chronic inflammatory 
condition averaged 6.38 cycles of therapy (SD = 0.89), and lastly those patients with a 
history of two or more chronic inflammatory conditions averaged 8.45 cycles of 
nivolumab treatment (SD = 1.02) (Figure 4.3). 
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Figure 4.2: MCC nivolumab-treated patients treated March 2015 to February 2016. 
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Figure 4.3:  The effect of chronic inflammatory conditions on cycles of nivolumab. 
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PD-L1 expression of tumor tissue analysis 
Seven patients were found to have banked FFPE lung tumor tissue samples in the MCC 
biospecimen core. No information was present as to when sample was isolated during 
the patient’s treatment history. Three patients demonstrated no PD-L1 expression, two 
had expression on macrophages only, one showed less than 10% expression, and one 
had greater than 20% PD-L1 expression (Table 4.1). Three of those seven patients 
exhibited objective response to nivolumab treatment (i.e. >6 cycles of therapy); however, 
response was not correlated with PD-L1 expression. The patients that exhibited a 
positive tumor PD-L1 expression had a histology of squamous cell carcinoma. The 
patient whose sample had a PD-L1 expression greater than 20% had a history of chronic 
inflammatory conditions while the patient with tumor PD-L1 expression less than 10% 
did not have a history of chronic inflammatory conditions.  
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Table 4.1:  PD-L1 expression and history of inflammation for nivolumab-treated NSCLC 
patients. 
Patient 
ID Gender Histology 
Response on 
Nivolumab 
Inflammatory 
Disease 
PD-L1 
expression by 
IHC 
BH556 F adenocarcinoma NR-expired yes 
macrophages 
only 
BH2022 F adenocarcinoma R yes 
macrophages 
only 
BH2023 M 
squamous cell 
carcinoma NR-expired no <10% 
BH2024 F adenocarcinoma Lost to follow-up no no 
BH2025 F adenocarcinoma Lost to follow-up no no 
BH2026 M 
squamous cell 
carcinoma NR-expired yes ~20% 
BH2027 F N/A NR-expired yes no 
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Outcome Data Results 
The health outcomes research aim provided a much larger pool of patients to assess. 
Table 4.2 displays the baseline demographic and clinical characteristics of the study 
population by exposure group. Eligibility criteria were met by 3,252 ICI-treated patients 
from whom a complete dataset was available. Among the ICI-treated cancer patients 
identified, 2,339 had a history of chronic inflammation and 913 patients did not. There 
were 432 patients who passed away within one-year of diagnosis. The mean age of 
patients in the chronic inflammation cohort was 62.3 (SD = 12.31) and in the no chronic 
inflammation cohort was 52.6 (SD=12.72). In both exposure groups, melanoma and lung 
cancer were the only two diagnosed cancers, and the majority of patients were diagnosed 
with melanoma (lung cancer = 815 and melanoma = 2,612 patients). Over 95% of the 
entire patient population was previously treated with cytotoxic chemotherapy. Of the 
chronic inflammation cohort, 42% were treated previously with radiotherapy whereas 36% 
of the no chronic inflammation cohort was treated with radiotherapy. In the chronic 
inflammation cohort, 1,987 were obese, 1,761 were diagnosed with diabetes, 609 with 
hypertension, 854 with hyperlipidemia and 1,582 with COPD.  
 
The number of matched pairs post-propensity score matching were 1,948  for the chronic 
inflammations versus no chronic inflammation comparison. Upon stratification by cancer 
type, the number of matched pairs for lung cancer and melanoma were 367 and 1,531, 
respectively. While baseline differences existed among exposure groups, matching 
provided samples that had minimal differences (Table 4.3). Four clinical variables 
(myocardial infarction, congestive heart failure, peripheral vascular disease and 
cerebrovascular disease) did not meet standardized differences scores below 0.10, that 
which is accepted to be balanced between cohorts. To account for these differences, 
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these four variables were included as covariates in the Cox proprotional hazard regression 
model. Table 4.4 displays the HR and associated 95% CI for the effect of the exposure 
group on on-year survival within the propensity-matched sample. Pre-existing chronic 
inflammation improved overall survival compared to no history of chronic inflammation 
(HR 1.23, 95% CI 1.01-1.50). When stratified by cancer, this observation held true 
specifically in patients with melanoma (HR 1.26, 95% CI 1.01-1.58). No differences were 
observed in patients diagnosed with lung cancer (HR 1.35, 95% CI 0.82 – 2.23).  
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Table 4.2:  Baseline demographics for all immune checkpoint inhibitor treated patients. 
  Chronic Inflammation No History 
  Mean Std. Dev Mean Std. Dev 
Age 62.3 12.31 52.56 12.72 
CCI 9.65 2.4 7.63 2.6 
  N (2,339) % N (913) % 
Gender (M) 1518 64.9% 495 54.2% 
Urban 398 17.0% 145 15.9% 
CCI Category 2,339   913   
1 37 1.6% 113 12.4% 
2 67 2.9% 13 1.4% 
3 48 2.1% 8 0.9% 
4 2187 93.5% 779 85.3% 
Obesity 1987 85.0% 0 0.0% 
Diabetes 1761 75.3% 0 0.0% 
Hypertension 609 26.0% 0 0.0% 
Hyperlipidemia 854 36.5% 0 0.0% 
COPD 1582 67.6% 0 0.0% 
Myocardial Infarction 140 6.0% 5 0.5% 
Congestive Heart Failure 229 9.8% 8 0.9% 
Peripheral Vascular 
Disease 657 28.1% 73 8.0% 
Cerebrovascular Disease 705 30.1% 114 12.5% 
Dementia 145 6.2% 26 2.8% 
Rheumatism 53 2.3% 19 2.1% 
Peptic Ulcer Disease 56 2.4% 8 0.9% 
Mild Liver Disease 713 30.5% 209 22.9% 
Paralysis 69 2.9% 16 1.8% 
Renal Disease 189 8.1% 4 0.4% 
Cancer 2325 99.4% 876 95.9% 
Severe Liver Disease 19 0.8% 3 0.3% 
Metastatic Cancer 2,184 93.4% 783 85.8% 
HIV/AIDS 7 0.3% 3 0.3% 
Lung Cancer 679 29.0% 136 14.9% 
Melanoma 1,839 78.6% 773 84.7% 
Previous Chemotherapy 2,272 97.1% 863 94.5% 
Previous Radiation 971 41.5% 330 36.1% 
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Table 4.3:  Standardized differences post-propensity score matching. 
Cohort (Chronic Inflammation) 
Obs Variable Std. Diff 
1 Age 0.117 
2 Charlson Comorbidity Index (CCI) 0.517 
3 Gender 0.035 
4 Region 0.050 
5 Urban 0.046 
6 CCI Category 0.159 
7 Myocardial Infarction 0.231 
8 Congestive Heart Failure 0.298 
9 Peripheral Vascular Disease 0.299 
10 Cerebrovascular Disease 0.228 
11 Dementia -0.011 
12 Rheumatism -0.006 
13 Peptic Ulcer Disease 0.003 
14 Mild Liver Disease 0.024 
15 Paralysis 0.021 
16 Renal Disease 0.021 
17 Cancer 0.021 
18 Severe Liver Disease 0.021 
19 Metastatic Cancer 0.021 
20 HIV/AIDS 0.021 
21 Chemotherapy 0.0722 
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Table 4.4: One-year survival analysis for ICI-treated patients. Hazard ratios (HR) and 
associated 95% confidence intervals (CI) for the impact of chronic inflammation on 
survival within the propensity-matched sample. Results include entire treated group (All 
Selected Cancers) and stratified by cancer type. 
Stratification 
Patients with 
History of 
Chronic 
Inflammation 
Patients without 
history of 
Chronic 
Inflammation 
HR 95% CI 
All Selected 
Cancers 1,218 730 1.23 1.01 1.5 
Lung 240 127 1.35 0.82 2.23 
Melanoma 949 582 1.26 1.01 1.58 
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D. DISCUSSION 
 
ICIs have been enthusiastically accepted by clinicians as a promising option for patients 
well into their malignancy treatment pathway. PD-1 inhibitors such as nivolumab and 
pembrolizumab are gaining additional FDA approvals for several malignancies, including 
becoming first line treatment options in metastatic disease (216). The high financial 
costs of these agents justify careful consideration when selecting a patient to be treated. 
The one guiding principle presently used clinically is PD-L1 expression on tumors. This 
diagnostic has inherent flaws and has not been able to objectively determine patients 
exhibiting long-term durable responses. Therefore, we undertook these studies with the 
hypothesis that comorbid conditions, specifically those that affect the inflammatory 
conditions in the periphery and in the tumor microenvironment, would correlate with 
response to nivolumab in NSCLC patients.  Furthermore, closer examination of these 
comorbid conditions, may allow us to identify a molecular signature going forward that 
serves as a robust predictor of response. Our hypothesis is anchored in the concept that 
while chronic inflammation may create genetic alterations that induce the growth of 
tumor cells, the presence of those immune factors in peripheral blood, and in the tumor 
microenvironment, may prime an immune response once the inhibition of the immune 
checkpoint is released.  
 
The first local, retrospective study presented herein identified an association of chronic 
inflammatory conditions with the response of cancer patients treated with nivolumab. 
Our patient population consisted of a small group of adult patients with metastatic 
NSCLC disease who progressed after platinum chemotherapy. As expected, twenty 
percent of our population exhibited long-term durable responses matching the results of 
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other long-term nivolumab treatment studies. Patients with a history of chronic 
inflammatory conditions, including metabolic syndrome disorders or COPD, stayed on 
nivolumab therapy for a longer period averaging a higher number of cycles received. In 
addition, those patients with a history of more than two of these conditions received an 
average number of nivolumab cycles greater than those patients with only one condition. 
Of the seven tumor samples analyzed for PD-L1 expression, two exhibited positive 
expression and neither correlated with improved response. PD-L1 expression alone did 
not correlate with response however the patient with PD-L1 expression greater than 20% 
also had a comorbid history of chronic inflammation.  
 
Components of the circulating immune response might better indicate response to ICI 
agents than PD-L1 expression alone. Systemic inflammation has been shown to 
increase oxidative stress, activate circulating neutrophils and lymphocytes, and alter 
levels of inflammatory mediators (i.e. TNF-α, IL-6, IL-8 & C-reactive protein) (217, 218). 
The tumor microenvironment may have altered levels of cytokines, growth factors, and 
chemokines that affect tumor cell proliferation, survival and immune evasion due to 
chronic inflammation (4). Chronic obstructive pulmonary disease (COPD), a chronic 
inflammatory condition, is associated with elevated IFN-γ + and TNF-α+ CD8+ T-cells 
when compared with healthy controls (219). TNF-α is recognized by two receptors, TNF-
α R-1 and TNF-α R-2, the latter of which is expressed mainly on immune cells (220). It 
has been shown that high concentrations of this cytokine can induce an anti-tumor 
response in sarcoma mouse models (221). In addition, NSCLC patients with elevated 
TNF-α in tumor islets have had favorable survival rates (222). The interplay between 
chronic inflammation and immune response has been theorized as an important part of 
immune checkpoint inhibition (223, 224). PD-L1 expression can be induced by interferon 
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(IFN) activity, and indirectly by IL-12, in both endothelial normal cells and breast cancer 
cells (207, 208). Importantly, activated oncogenes can transduce intracellular signaling 
events leading to aberrant PD-L1 expression in cancer cells (225). Taube and 
colleagues investigated the signaling events that induce PD-L1 expression and 
demonstrated that many cytokines were overexpressed in melanoma cell lines, including 
RANTES, CXCL1, IL-10, IL-18 and IL-21. In vitro stimulation of melanoma cells by IFN-γ 
induced PD-L1, but recombinant forms of the other cytokines failed to increase cell 
surface expression of PD-L1 with or without IFN-γ (54). However, incubation of activated 
T-cells with IL10 (+/- IFN-γ) induced expression of PD-L1 on monocytes thereby 
reducing T-cell activation (51). In an open-label, phase 2 randomized controlled trial, 
patients with NSCLC who progressed post-platinum chemotherapy were allocated to 
treatment with atezolizumab (PD-L1 inhibitor) or docetaxel (75). In an exploratory 
analysis, effector T cell INF-γ gene signatures, defined by CD8A, GZMA, GZMB, IFNγ, 
EOMES, CXCL9, CXCL10, and TBX21 were assessed. Patients with high expression of 
the IFN- γ signature had improved overall survival with atezolizumab treatment 
compared to patients with low expression of this cytokine gene signature (HR 0.43, 95% 
CI 0.24-0.77).  
 
Our second aim was an observational cohort study and identified a significant effect on 
the overall survival of cancer patients who received immune checkpoint inhibitor 
treatment with previous comorbidity of a chronic inflammatory condition, replicating the 
institutional study. Upon stratification by cancer type, the improved survival advantage 
held true only in the melanoma population. Our Truven population of ICI-treated patients 
were identified from early 2011 to the end of December 2015. The earliest FDA approval 
of an ICI for the treatment of lung cancer was granted to nivolumab on March 4th, 2015 
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for the treatment of metastatic squamous NSCLC with progression on or after platinum-
based chemotherapy (184). This limited our follow-up and none of these patients 
completed one full year of follow-up to assess one-year mortality. Thus, additional years 
of data are necessary to fully vet the lung cancer population for the effect of chronic 
inflammation on response to ICI. This population suggests however that chronic 
inflammation does impact overall survival for ICI-treated patients. This health outcomes 
study improved and extended the results of the prior analysis with the inclusion of a 
large sample size and with the use of one-year overall survival as a measure of 
response.  
 
Limitations of the local retrospective study include the small population size as well as 
the use of cycles of nivolumab therapy as a surrogate for survival. The population size 
assessed in this study is 45 patients, which is enough to assess trends and correlations, 
but a much larger sized population of real patient data will be required to validate the 
findings of this study. Clinically, response is measured by two outcomes, PFS and OS, 
each allowing direct interpretation of how ICIs affect the tumor size and growth. Cycles 
of therapy, although may reflect the length of the treatment period and tolerance of the 
regimen, does not give us insight on the effect of ICIs on the tumor. The national health 
outcome study is subject to the limitations of all claims-based studies (182, 183). Claims 
data lack detailed information on laboratory values or tumor staging, which may have 
influenced the outcomes of this study. This study was limited to a one-year follow-up due 
to the availability of data. Lastly, while propensity score matching is known to reduce 
selection bias in non-randomized studies, it is possible that residual bias is present or 
that unmeasured confounders may have impacted these findings (158). This study is 
strengthened by a large sample size and the assessment of all-cause mortality. 
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Obesity and Inflammation 
Obesity is a worldwide epidemic which is characterized by inflammation of adipose 
tissue eventually leading to the development of type 2 diabetes, cardiovascular disease 
and cancer (226). Immunologically, adipocytes represent a large source of immune cells 
and inflammatory cytokines including T cells, B cells, macrophages and neutrophils 
(227). The number of leukocytes in the blood is increased as compared to patients with 
a normal body surface area (BSA) (228). Monocytes, specifically macrophages, migrate 
to adipose tissue and overwhelming have an M1 configuration relative to M2, leaning 
into a pro-inflammatory function (229). The increased release of leptin from adipocytes 
of visceral fats act upon Th1 and Th2 cells inducing the production of IL-2 and IL-4 
activating the proliferation of T cells (230). In addition to the release of leptin, resistin and 
visfatin induce the production of IL-1β, IL-6, IL-8 and IL-12 (231). Adipose tissue from 
obese patients with colorectal cancer expressed elevated levels of PD-L1 and PD-L2 
(232). The presence of adipose tissue from obese patients that is present throughout the 
development of the tumor may instill a pro-inflammatory tumor microenvironment. The 
adipose tissue surrounding the tumor site would potentially secrete the same cytokines 
and induce the immune cell populations present in the periphery as well.  
Diabetes and Inflammation 
Obesity is closely linked to the advent of type 2 diabetes mellitus (T2DM) which itself is 
associated with several macrovascular (coronary artery disease, stroke) and 
microvascular complications (diabetic retinopathy, nephropathy and neuropathy) (233). 
In an analysis of inflammatory cytokine concentrations from monocytes and neutrophils 
in patients with T2DM, it was observed that the concentrations of TNF-α, IL-6, IL-1β, IL-
10, IL-12, IL-8, IFN-β and IFN-γ were all normal compared to non-diabetic volunteers 
(234). However, when assessing the gene expression, cytokine and TLR gene profiles 
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were enhance in T2DM patients compared to non-diabetic volunteers. TNF-α, IL-6 and 
IFN- β mRNA levels in monocytes and neutrophils were elevated in patients with good 
glycemic control however patients with poor glycemic control presented with a reduced 
inflammatory expression and did not differ from the non-diabetic volunteers. Genome-
wide expression profiling of patients with diabetes shows an up-regulation of CD274, 
otherwise known as PD-L1 (235). This is to prevent the pancreatic islets from 
autoimmune destruction but may be allowing for the up-regulation of PD-L1 on tumors 
increasing the likelihood of success with ICI therapy. The control of the diabetic state 
also directly influences the inflammatory environment. The diagnosis alone of diabetes 
prior to ICI therapy may not be a robust measure of predicting response without the 
assessment of glycemic control.  
COPD and Inflammation 
COPD is typically caused by exposure to inhaled toxins such as tobacco smoke or dust 
and has been deemed a risk factor for the development of lung cancer. Just like with 
T2DM, the severity of COPD dictates the inflammatory cytokines present in the lung 
(236).  IL-6, IL-8 and IL-10 were independently associated with worse airflow obstruction 
(P<0.05). In a full regression model with all clinical covariates including IL-2, IL-6, IL-8, 
IL-10, TNF-α and INF-γ, IL-6 accounted for the largest portion of the variance of forced 
expiratory airflow at 1 sec (FEV1%). In a cohort of 10,300 COPD patients, blood was 
drawn and spun down during their initial visit and then again in their 5-year follow-up visit 
(237). Elevated IL-6 was associated with rapid decline of airflow at 5 years. This 
observations held despite stratification by COPD treatments used. In malignancies, IL-6 
was seen to play a part in tumor microenvironment regulation and the induction of 
metastasis through down-regulation of E-cadherin (238, 239). IL-6 exposure in cervical 
carcinoma cell lines induced IL-6R and STAT3 expression resulting in the down-
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regulation of E-cadherin. IL-6 complexes with IL-6R then associated with signal-
transducing membrane protein gp130. GP130 dimerization occurs and is followed by 
rapid activation of the Janus kinase (JAK) family. Activated JAKs then phosphorylate 
tyrosine residues on the receptor. Signal transducer and activator of transcription 
proteins (STATs) with SH2 domains are recruited to the receptor where they are 
tyrosine-phosphorylated by JAKs. The activated STATs then dimerize and translocate to 
the cell nucleus where they induce transcription of target genes. STAT3 activation 
suppresses Toll-like receptor 4 (TLR4) ligand and lipopolysaccharide (LPS)-mediated 
dendritic cell (DC) maturation and activation (240). In addition, STAT3 activation by IL-6 
suppresses MHC class I expression on DCs and attenuates CD4+ Th1 helper T cell 
response through activation of lysosomal protease (241). Th1 cells produce IL-2 and 
IFN-γ which are involved in the activation of cytotoxic T lymphocytes (242). 
Augmentation of IFN-γ levels directly impact PD-L1 expression on tumor cells (243).  
 
E. CONCLUSIONS 
 
Our data show that a patient history of chronic inflammation correlates with ICI 
response. In an institutional IRB-approved study, former and current NSCLC patients 
treated with a PD-1 inhibitor were assessed for a correlation between their history of 
chronic inflammation and ICI response, and those with a history of at least one chronic 
inflammatory condition received more cycles of nivolumab therapy than those patients 
who did not have these conditions. Using the national health outcomes data, our work 
shows that patients with a history of chronic inflammatory comorbidities have improved 
one-year survival rates as compared to ICI-treated patients without a history of chronic 
inflammation. These results are in accordance with the findings of the single-center 
retrospective study.  
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CHAPTER 5  
A. OVERVIEW 
 
My work that determined that cancer patients with a history of a chronic inflammatory 
condition improves the response to immune checkpoint inhibitors (ICIs) was an initial 
step in the development of a blood-based biomarker of response to ICI therapy. 
Currently in clinical practice, the gold standard for isolating samples to develop 
biomarkers of response in cancer is tumor tissue analysis. It is amenable to many 
measures of biological activity including nucleic acid sequencing and assessment of 
protein expression by immunohistochemistry (IHC) (244). Characterization of the tumor 
specimen, from a biopsy or from resected material, can measure molecular features 
specific to the patient; however, it represents a static image and does not characterize 
the dynamic changes to the tumor over time. Importantly, even though this snapshot is 
rich in information, it does not represent the inter- and intratumoral heterogeneity of a 
tumor (245). Further, logistical issues may prevent acquisition of tumor tissue. Eighty 
percent of metastatic non-small cell lung cancer (NSCLC) patients have limited tissue 
availability and up to 31% do not have accessible tissue at all (246) .The performance 
status of NSCLC patients may not allow for interventional biopsy procedures at the 
moment needed for biomarker evaluation (247). Considering the limitations of tumor 
tissue, liquid biopsies have become more appealing as they are much more accessible 
for sampling, amenable to serial sampling throughout treatment, and flexible for multiple 
testing platforms (flow cytometry, ELISA, mass spectrometry, etc.). Liquid biopsies may 
contain circulating tumor cells (CTCs), non-hematological cells with malignant features 
encompassed in the tumor microenvironment, and cells of the immune system (248). 
Large comparison studies that assess the equality of DNA analysis of CTCs and tumor 
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tissue biopsies demonstrate that the liquid biopsy approach gives a faithful measure of 
DNA features compared with tumor tissue (249, 250). In addition to CTCs and cells of 
the immune response, sampling the periphery can also measure tumor-derived 
exosomes, extracellular vesicles that contain cytokines present in the tumor 
microenvironment. Serial sampling of the periphery using liquid biopsies permits tracking 
of efficiency and toxicity of treatment allowing the oncologist to anticipate the most 
effective subsequent treatments (251).  
 
I believe that liquid biopsy of NSCLC patients can provide a sample(s) for development 
of a biomarker of response to ICI that exceeds the performance of the companion 
diagnostic (IHC for PD-L1 expression) for PD-1 and PD-L1 inhibitors. Development of a 
robust biomarker of response can improve efficacy and control the cost of therapy in 
patients who have few therapeutic options, like recurrent lung cancer patients. We 
hypothesized that chronic inflammation creates an environment that promotes an anti-
tumor immune response and the molecular marker of that response can predict an anti-
tumor response in NSCLC patients to immune checkpoint inhibitors. The primary goal for 
this study was to measure pro-inflammatory cytokine levels and immune cell subtype 
populations in healthy subjects and patients with metabolic syndrome, chronic 
obstructive pulmonary disorder (COPD), and NSCLC to develop predictive biomarkers of 
response to PD-1 and PD-L1 inhibitors. We expect this work to also be impactful in 
further understanding the biological role of chronic inflammation in response to ICI.  
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B. METHODS 
 
Patient Selection and Monitoring 
We received institutional IRB approval for this clinical study to recruit patients diagnosed 
with metabolic syndrome disorders (MetS; hyperlipidemia, hypertension, diabetes mellitus 
or obesity), COPD or NSCLC. These cohorts were selected as COPD and MetS 
populations are expected to have a high degree of chronic inflammation, healthy subjects 
were expected to have no history of chronic inflammation and NSCLC to have a mixed 
history. Healthy subjects were included in this study who did not self-report any of the 
aforementioned conditions and history of smoking. All subjects/patients were aged 50 
years or older. We will enroll 20 healthy subjects and 20 each of the MetS and COPD 
cohorts. We will enroll 90 NSCLC patients. All patients enrolled are 50 years or older and 
women will be postmenopausal. Enrolled patients were excluded if they exhibited flu or 
cold symptoms or the use of antibiotics in the two weeks prior to clinic visit, diagnosis of 
an autoimmune disorder or treatment with any immune modulating therapies or lastly, 
smoking history (only for healthy volunteer cohort). All patients gave written informed 
consent. The study protocol was approved by the institutional review board (IRB) of the 
University of Kentucky. NSCLC cohort patients were recruited at the time of treatment with 
a PD-1 or PD-L1 inhibitor. These included nivolumab, pembrolizumab and atezolizumab. 
Blood samples were taken from patients with histologically confirmed NSCLC. Blood 
samples were drawn right prior to ICI infusion. All NSCLC patients were monitored via 
monthly (Months 1-3) and 3-month (Months 6, 9, and 12) chart review. Data collected 
includes number of treatment cycles, CT scan results, objective response, patient survival, 
and disease state measures (recurrence, progression, etc.). Durable response defined as 
ongoing treatment with complete disappearance of all lesions or decrease in tumor burden 
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by > 50% relative to baseline after 6 cycles of therapy per the immune-related response 
evaluation criteria in solid tumors (irRECIST) (252). 
 
Data Collection and Analysis 
Enrollment of 20 subjects/patients of the healthy, MetS and COPD cohorts will provide 
90% power to detect difference in expression of several inflammatory cytokines (see 
power analysis below) using a two-sided, two-sample t-test with 1% significance 
level.  Adjustment in significance level was employed due to multiple comparisons 
between healthy versus MetS and COPD cohorts. Frequency matching will be employed 
to ensure similar distribution with respect to gender among the subject cohorts. 
Assuming a moderate correlation coefficient equal to 0.30 between each cytokine level 
and PD-L1 expression levels, enrollment of 90 NSCLC patients will provide 82% power 
based on a two-sided t-test with 5% significance level.  
Power calculations 
Power was determined by reviewing the literature for evidence of whether physiological 
levels of cytokines were significantly different among COPD and metabolic syndrome 
patients, and healthy adults (e.g. IL-4, IL-5, and TNFα). From these reports, we 
determined that a small sample size per group provide power to detect differences in 
cytokine levels (253-255). Specifically, we will compare each cytokine level between 
NSCLC and each of the MetS, COPD and healthy cohorts.  Statistical power for the 
NSCLC cohort was primarily based on the association of PDL1 expression with clinical 
outcome and this will be carried out as an exploratory analysis.  Other data analysis 
plans include two group comparisons of each cytokine between healthy and each of the 
MetS, COPD and NSCLC groups using two sample t-test, and analysis of variance 
(ANOVA) for comparison across groups.    
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Multiplexed ELISA  
Consented patients had two blood samples drawn in 6-mL K2+EDTA+ in the clinic and, 
those were transported to the lab. Each blood sample (10-12ml) was immediately 
centrifuged at 250 g for 10 minutes at room temperature. The plasma from each patient 
or normal donor was aliquoted in cryotubes and stored in -80C. Cytokine profiles were 
assessed by multiplex human cytokine ELISA assay (Quansys Biosciences, Logan, UT, 
USA) to determine the relative levels of 15 pro-inflammatory cytokines. The 15 cytokines 
included were IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12p70, IL-13, IL-15, IL-17, IL-
23, IFN-γ, TNF-α and TNF-β. The multiplexed assay was used to reduce volume of 
sample needed and to standardize the assay using purified cytokines as controls. 
Cytokine concentrations were measured then calculated by Q-View software version 
3.09. All samples were assayed in duplicate and the mean value was reported. 
Flow Cytometry 
Due to known degradation of cell surface markers such as PD-L1 when samples are 
cryopreserved, flow cytometry was conducted promptly after blood sample collection 
(256). Following plasma removal, the remaining blood sample was processed through a 
Ficoll Hypaque gradient and centrifuged at 400 g for 20 minutes at room temperature to 
separate plasma from the buffy coat  which contains peripheral blood mononuclear cells 
(PBMC) (257). Cells were washed twice in buffer (PBS). After PBMC isolation, 1 x 106 
cells were distributed to 10 FACs tubes. Cells were pelleted by centrifugation, 
resuspended in 400 μl of buffer (PBA). Cell suspensions were stained with 
Phycoerythrin-conjugated anti-human CD279 (PD-1), fluorescein isothiocyanate-
conjugated anti-human CD3, phycoerythrin-cyanine 5-conjugated anti-human CD4, 
phycoerythrin-cyanine 7-conjugated CD8, phycoerythrin-conjugated anti-human CD274 
(PD-L1), fluorescin isothiocyanate-conjugated anti-human CD14 and allophyocyanin-
conjugated anti-human CD45 antibodies. Secondary antibodies for CD3, CD4, CD8, 
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CD14, CD45, PD-1 and PD-L1 bound to fluorophores were added to FACs tubes and 
incubated in cold room over 20 minutes.  Immune cell subtype populations sorted using 
the Attune™ flow cytometer. Immune cell populations analyzed included CD3+ only, 
CD3+CD4+, CD3+CD8+, CD4+PD-1+, CD8+PD-1+, CD14+CD45+ and 
CD14+CD45+PD-L1+. Flow cytometry data analysis was performed using FlowJo 
version 7.6.5 (Tree Star). 
Statistical analyses 
Statistical analyses were conducted in collaboration with Katherine Thompson, PhD of the 
Department of Statistics at the University of Kentucky. Distribution of continuous variables, 
including cytokine concentrations and immune cell populations, were described by their 
mean and standard deviation. Four cohort comparisons (Healthy, MetS, COPD, NSCLC) 
were done using analysis of variance (ANOVA). A p-value < 0.05 was considered as 
statistically significant. All analyses were performed using SAS software (SAS, Cary, NC, 
USA) and R Package software (Version 3.40) (258). Cytokine concentrations, expressed 
in pg/ml, were first assessed by Fisher’s exact test for detection in plasma.  Cytokines that 
were detectable were then compared by ANOVA followed by post-hoc t tests with 
reference to NSCLC cohort. Cytokine concentrations were natural log-transformed. 
Immune cell subtype populations derived from flow cytometry were compared using 
ANOVA followed by post-hoc t tests with reference to NSCLC cohort. Percentages of 
specific immune cell populations were transformed by taking the arcsine of the square root 
for ease of depiction. ANOVAs followed by post-hoc t tests were used for assessment with 
reference to NSCLC to determine if any cohort significantly differed in immune cell 
subtypes. Finally, to determine whether immune cell subpopulations and/or cytokine levels 
predict response to ICI in NSCLC patients, a logistic regression model was employed. It 
is likely that this model would not be appropriate with these data due to perfect separation 
of responders from non-responders, so feasible solutions algorithm (FSA) with the 
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criterion of Bhattacharrya distance (B-distance) will be utilized to assess pairs of 
observations that can provide “feasible solutions” for prediction of ICI response in the 
NSCLC cohort (259-261). Perfect separation typically occurs in small samples with 
unbalanced and/or highly predictive variables. Separation occurs if the predictor is 
associated with only one outcome value when the predictor is greater than some constant 
(262). This means the maximum likelihood estimate of the logistic slope coefficient does 
not exist. FSA is a technique that allows the assessment of predictive capabilities of 
different combinations of pairs of variables to determine the pair(s) with the best predictive 
ability of the outcome of interest. This technique serially tests pairs based on a selected 
criterion. FSA in turn can employ B-distance, a measure of the relative proximity of two 
samples taking into account shape, range and direction of the sample data. The center 
point of two samples may overlap, but when considering each individual data value, the B 
distance may be different and highlight variables of interest. 
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Figure 5.1:  Clinical study protocol 
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C. RESULTS 
 
The study is ongoing and has recruited 36 patients to date, six in the COPD cohort and 
ten in each of the remaining cohorts. The study will continue to achieve target accrual; 
however, herein I discuss the interim analysis of the data collected. First, not all 
cytokines could be detected (Detect: Y/N) from plasma using multiplexed ELISA (Table 
5.1). Cytokines that were detectable in greater than 50% of the subject/patient samples 
included IL-4, IL-6, IL-13, IL-23, IFN-γ and TNF-α. IFN-γ was evaluable in all patient 
samples. Certain cytokines were more readily detectable in certain cohorts. IL-4 
concentrations were detectable in most healthy subjects but not in any other cohort. IL-6 
concentrations were detectable in patients with NSCLC and healthy subjects. Six 
detectable cytokines were compared for differences among the cohorts (Figure 5.2). In 
NSCLC patients, IL-4 levels were significantly decreased compared to the healthy 
subject cohort (P=0.0066). In addition, the COPD cohort trended toward increased IL-4 
concentrations compared to NSCLC patients (P=0.1888). IL-6 demonstrated lower 
concentrations in the MetS cohort compared to the NSCLC cohort (P=0.0691). IL-13 
levels are decreased in NSCLC patients compared to healthy subjects (P=0.0788). 
Although IFN-γ was detectable in all patients, there were no significant differences 
among the four cohorts. TNF-α did not show any significant differences among the 
cohorts.  
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Table 5.1:  Cytokine measurements organized by cohort. 
  Detect Healthy COPD MetS NSCLC P-value 
IL-1a (pg/ml) N 3 4 5 6 0.5237 
Y 7 2 5 4 
IL-1b (pg/ml) N 7 4 10 10 0.0347 
Y 3 2 0 0 
IL-2 (pg/ml) N 8 6 10 10 0.2381 
Y 2 0 0 0 
IL-4 (pg/ml) N 2 4 10 10 <.0001 
Y 8 2 0 0 
IL-5 (pg/ml) N 7 5 10 10 0.0922 
Y 3 1 0 0 
IL-6 (pg/ml) N 4 4 9 4 0.0678 
Y 6 2 1 6 
IL-10 (pg/ml) N 8 5 10 10 0.2297 
Y 2 1 0 0 
IL-12p70 (pg/ml) N 5 4 10 10 0.0043 
Y 5 2 0 0 
IL-13 (pg/ml) N 7 5 10 10 0.0922 
Y 3 1 0 0 
IL-15 (pg/ml) N 0 2 0 1 0.1162 
Y 10 4 10 9 
IL-17 (pg/ml) N 6 5 6 9 0.3562 
Y 4 1 4 1 
IL-23 (pg/ml) N 3 4 3 5 0.4137 
Y 7 2 7 5 
IFN-y (pg/ml) N 0 0 0 0 N/A 
Y 10 6 10 10 
TNF-a (pg/ml) N 1 2 1 0 0.2908 
Y 9 4 9 10 
TNF-b (pg/ml) N 5 4 10 9 0.0288 
Y 5 2 0 1 
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 Figure 5.2: Comparison of IL-4, IL-6, IL-13, IL-23, IFN-γ, and TNF-α levels by cohort. 
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The second goal was to investigate the proportions of relevant immune cell subtypes in 
each cohort and compare among cohorts. The immune cell subsets chosen for study 
include CD8+ T cells, CD4+ T cells, CD14+CD45+ monocytes, PD-1+ T cells and PD-
L1+ monocytes. Lymphocyte populations were assessed using CD3, CD4 and CD8 
markers. Monocyte populations were then assessed using the markers CD14 and CD45. 
We found significant differences among the several cohorts (Figure 5.3). Healthy 
subjects, patients diagnosed with MetS, and those with COPD all had significantly 
elevated levels of CD3+ lymphocytes compared to patients with NSCLC (P=0.0094, 
P=0.0043, P=0.0026, respectively). There were no detectable differences between 
CD3+CD4+ lymphocyte populations among all four cohorts; however, there was a 
significantly increased level of CD3+CD8+ lymphocytes in the NSCLC cohort compared 
to both healthy subjects and MetS patients (P=0.0344, P=0.0099, respectively). 
Interestingly, the CD3+CD8+ immune cell subtype did not differ between NSCLC and 
COPD patients. There were no distinguishable differences in CD4+PD-1+ or CD8+PD-
1+ populations among the cohorts. Of note, monocyte populations were significantly 
elevated in patients with NSCLC compared to the MetS and COPD cohorts (P=0.0293, 
P=0.0025, respectively). However, the comparison of CD4+CD45+PD-L1+ immune cell 
subtypes showed no difference among cohorts. 
 
Finally, we examined whether any of the measured parameters might predict durable 
response to ICI in the NSCLC cohort. Of the ten patients in the NSCLC cohort, seven 
met our criteria for durable response. Eleven variables were selected to be included in a 
logistic regression model; six cytokines (IL-4, IL-6, IL-13, IL-123, IFN-γ, TNF-α) and 5 
immune cell populations (CD3+ Only, CD3+CD8+, CD8+PD-1+, CD14+CD45+, 
CD14+CD45+PD-L1+). Logistic regression models could not be fit due to perfect 
separation between the 7 responders and 3 non-responders. In this case, all durable 
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responders are associated with a cytokine concentration above or below a certain level. 
For maximum likelihood estimates to exist, there must be some overlaps in the two 
distributions. We then used FSA, with a criterion of B distance, to find possible solutions 
that might be predictive. Out of 25 times FSA was run, two pair of measures were 
determined to be predictive of response (Figure 5.4A). The combination pair of CD3+ 
only and CD8+PD-1+ immune cell populations had the largest B distance of 2.88. This 
pair was chosen 15 of the 25 trials. Elevated CD8+PD-1+ populations and low CD3+ 
only populations were predictive of non-responders (Figure 5.4B). Another pair was 
chosen for the remaining 10 trials and that is the combination pair of CD14+CD45+ 
monocyte population and IFN-γ cytokine concentration with a B distance of 2.34. 
Increased concentrations of IFN-γ and elevated monocyte populations were indicative of 
response (Figure 5.4C). 
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 Figure 5.3:  Comparison of immune cell populations by cohort. 
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        Figure 5.4: Feasible solutions algorithm (FSA) assessment to predict durable response in NSCLC cohort. 
Variable 1 Variable 2 B Distance Trials 
CD3+ CD8+ PD-1+ 2.878134 15 
CD14+ CD45+ IFN-γ 2.340578 10 
A 
B C 
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D. DISCUSSION 
 
 
Recent literature has revealed that the presence of inflammatory cells within the tumor 
microenvironment is associated with an improved clinical outcome after treatment with 
ICIs (263). The concept of “immune contexture” was established, assessing the type, 
density, functional orientation and location of the immune cells within distinct tumor 
regions (264). To establish a viable clinical utility for this concept in ICI-treated patients, 
the immunoscore was formed that is based on the immune cell subtype populations. The 
immunoscore can be based on any combination of the lymphocyte or monocyte 
populations but most researchers noted the use of CD3+ and CD8+ tumor-infiltrating 
lymphocytes (TILs). 
  
To date, there has been no standardized scoring system of immune cell profiles 
combined with cytokines concentrations from peripheral blood to predict response from 
ICI treatment in NSCLC patients. Our goal was to use our prior work that established 
that chronic inflammation associates with response to PD-1 and PD-L1 inhibition and 
extend that work to measure molecular markers of inflammation, specifically 
inflammatory cytokines and immune cell subsets in the periphery of patients with known 
chronic inflammation or NSCLC. The inclusion of healthy, MetS and COPD cohorts was 
to compare different states of known chronic inflammation to the mixed state expected 
within the NSCLC cohort with the expectation that NSCLC patients that are responders 
to ICI would have an immune profile similar to those with chronic inflammation. We 
sought to determine whether peripheral biomarkers could also predict response to ICI 
therapy in NSCLC and whether the inflammatory markers are different in NSCLC 
compared with other cohorts of non-cancer, chronically inflamed patients.  
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While this study is ongoing, preliminary analysis of the data has provided insights into 
the molecular interactions of immune response and cancer. The primary endpoints 
analyzed are the differential expression of cytokine concentrations and immune cell 
subsets in NSCLC patients compared to patients with MetS or COPD. In our exploratory 
analysis, we have shown that immune cell subtype populations consisting of elevated 
CD3+ lymphocytes as well as low CD8+PD-1+ T cells, which distinguishes an exhausted 
cytotoxic T cell population, were predictive of response in NSCLC. CD3 is a T cell co-
receptor present on both T helper cells and cytotoxic T cells and is a general indicator of 
proliferation of lymphocytes (265). Elevated CD3+ expression suggests that the 
proliferative status of the immune response in NSCLC patients may indicate a readily 
actionable response to tumor cells following inhibition of the co-inhibitory signal. Low 
PD-1 expression on CD8+ cells has previously been shown to be a distinctive feature of 
nivolumab-treated patients showing clinical benefit with prolonged progression-free 
survival (HR 4.51; 95% CI 1.45-13.94) (266). With the development of PD-1 inhibitors 
that bind directly to the PD-1 receptor, it was hypothesized that the more PD-1 
expressed on T cells, the more anti-PD-1 antibody binding will occur. However, it is likely 
that elevated PD-1 expression indicates an exhausted state that, even with the binding 
of anti-PD-1 antibodies, the cytotoxic T cells cannot surmount a strong immune 
response to the tumor cells. With the variability of PD-L1 expression, PD-1 negative 
effector T lymphocytes provides an immune-privileged microenvironment with a positive 
impact on survival.  
 
We also identified a second combination of predictive markers, consisting of an immune 
cell subtype population and concentration of a certain cytokine was also predictive of 
response: increased CD14+CD45+ macrophage populations and IFN-γ concentrations. 
These results suggest activation of the innate immune response in NSCLC patients that 
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respond to ICI therapy. Specifically, innate immune response includes the activation of 
macrophages and the boosting of natural killer cell activity. Inflammatory monocytes 
selectively traffic to the sites of inflammation, produce inflammatory cytokines and 
contribute to local inflammation (267). CD14+ monocyte count increases correlate with 
presence of inflammatory conditions. Antitumor M1-polarized macrophages have the 
ability to direct cytostatic and cytotoxic effects on tumor cells, secret pro-inflammatory 
cytokines, and stimulate T cell immunity (268, 269). Investigations into the cooperation 
of lymphoid cells and macrophages led to the identification of IFN-γ as a regulator of 
macrophage tumoricidal activity (270). Two molecular signals are required for efficient 
induction of the M1 phenotype, TLR4 agonist LPS and IFN-γ (271). Importantly, IFN-γ 
has been identified as a cytokine that specifically upregulates PD-L1 expression on 
tumor cells, but it also plays a key role in the PD-L1 expression on macrophages. 
 
Completion of this study is required to ascertain whether these pairs of peripheral 
immune properties significantly predict responders to ICI treatment. Once accrual to all 
cohorts is complete, a validation cohort study will be required to compare the precision 
of this assay compared to the current standard of care, PD-L1 expression in the tumor. 
 
E. CONCLUSION 
 
Preliminary analysis of peripheral cytokine profiles and immune cell subset populations 
has identified several immune response molecular markers that describes differences 
among inflamed patients and healthy subjects and may be effective in predicting 
response to ICI therapy in NSCLC patients. We have shown that IL-4, IL-6, IL-13, IL-23, 
IFN-γ and TNF-α are detectable in peripheral blood. The cytokine profile present in 
NSCLC patients closely resembles that of COPD patients. Immune cell subset 
populations, including those with PD-1 receptor or PD-L1 can be assessed from PBMC 
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however there were no significant differences among cohorts. These data have given us 
insight into the alteration of the innate and adaptive immune responses that may be 
important for response to immune checkpoint inhibition. Importantly, these markers were 
generated from a minimally-invasive sample from peripheral blood and could be readily 
used by clinicians to continually monitor the patient for response and toxicity. Complete 
analysis of the entire study population will be required to confirm these findings and 
extend these observations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © Sherif M. El-Refai 2017
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CHAPTER 6  
A. SUMMARY OF RESULTS 
 
By coupling an observational clinical study design with a pharmacoepidemiological 
analyses, I have developed a testable hypothesis that chronic inflammation predicts 
response to ICI treatment in NSCLC patients. I then hypothesized that a liquid biopsy 
could be used to generate a biomarker of response to immune checkpoint inhibitors (ICI) 
in NSCLC patients by measuring molecular markers of inflammation. I concluded this 
work by demonstrating that this strategy could be utilized for the development of a 
peripheral blood biomarker assessment to predict response to ICI treatment. 
  
The first hypothesis that chronic inflammatory comorbidities, explored in Chapter 4, was 
tested by utilizing health outcomes research and pharmacoepidemiology principles to 
address the direct impact of chronic inflammatory comorbid conditions on response to 
ICI treatment without respect to a particular cancer. I developed an experimental 
strategy to identify a novel biomarker of response to ICI therapy. I initially utilized these 
principles to test hypotheses using large national databases based on the impact of 
treatment or exposure on specific biological pathways and processes. Specifically, in two 
previous studies,  I measured the impact of statin therapy on survival in cancer and then 
in the next study, calculated the incidence of autoimmune diseases in lung and renal 
cancer patients (108, 272). In the study outlined in Chapter 4, I found that, among the 
3,252 ICI-treated patients between 2011 and 2015, 2,339, with a history of chronic 
inflammation, had an improved one-year overall survival compared to those without 
chronic inflammation. This observation was in agreement with the findings of our local 
retrospective study analysis. Those results suggest that comorbidities that elicit a 
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constant, low-grade inflammatory state have a positive impact on the patient response to 
ICI treatment. It is anticipated that through further analysis and validation, the immune 
cell and cytokine profile brought about by this low-grade inflammatory state will yield a 
predictive diagnostic, achieved by liquid biopsy, to identify responders to ICI treatment in 
lung cancer.  
 
In Chapter 5, I analyzed inflammatory cytokine concentrations and immune cell 
populations in peripheral blood mononuclear cells (PBMCs) sampled from peripheral 
blood of non-small cell lung cancer (NSCLC) patients and identified differences among 
cohorts with and without inflammation and/or NSCLC and molecular profiles that may be 
predictive of response to ICIs. I characterized the inflammatory profile of NSCLC 
patients treated with programmed death receptor 1 (PD-1) or programmed death ligand 
1 (PD-L1) inhibitors and compared to the profile present in patients with chronic 
inflammatory disorders, either metabolic syndrome (MetS) or chronic obstructive 
pulmonary disorder (COPD).  I was able to identify six cytokines from peripheral blood in 
all cohorts including interleukin 4 (IL-4), IL-6, IL-13, IL-23, IFN-γ and tumor necrosis 
factor alpha (TNF-α) that were expressed above baseline. Of the six differentially-
expressed cytokine, significant differences were observed between certain cohorts. The 
cytokine profile of NSCLC most closely resembled that of the COPD cohort. NSCLC 
patients exhibited a smaller population of CD3+ lymphocytes relative to the other 
cohorts. Cytotoxic T cell (CD8+) levels in the NSCLC cohort were elevated compared to 
healthy and MetS populations, but did not differ from the COPD population. In addition, 
patients with NSCLC had a higher concentration of monocytes compared to MetS or 
COPD patients. Of these observations, I identified two pair of peripheral blood markers 
that may be predictive of response to ICI treatment; high CD3+ lymphocyte and low PD-
1 + cytotoxic T cell population levels or high monocyte levels coupled with high IFN-γ 
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concentrations. Finally, these results suggest that the peripheral blood can provide a 
means for minimally-invasive assessment of the state of the innate and adaptive 
immune response that may serve as a predictor of response to ICIs. This enables 
clinicians to sample for the predictor immune response from a peripheral blood test right 
prior to ICI treatment and determine whether this treatment path is suitable for this 
patient. Extending these observations to a more complete understanding of the 
underlying mechanisms that influence patient response to immunotherapies including 
ICIs will help shape future targeting strategies of the immune response.  
   
A. EXPERIMENTAL CONSIDERATIONS 
 
I utilized health outcomes data analysis to drive the design and analysis of the 
observational clinical study to test the central hypothesis that peripheral blood markers 
could be used to select patients primed for durable response for ICI therapy.  Using 
health outcomes approaches, we were able to assess specific health outcomes from a 
large national population and make broad inferences about the underlying interaction of 
cancer and chronic inflammation. Incorporating pharmacoepidemiology allowed us to 
then focus on specific properties of chronic inflammation to analyze in the clinical study.  
Finally, the use of clinical study model allowed us to directly explore the impact of 
specific cytokine levels and of immune cell populations in a prospective manner in 
patients undergoing therapeutic interventions.  
 
Although the interim results are promising, it is important to note that the clinical study 
has not met accrual goals and is thus not powered to address our central hypothesis that 
chronic inflammation improves the response to ICI treatment in NSCLC patients. 
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Completion of patient enrollment and peripheral blood assessment will be needed to 
identify the appropriate immune markers to further validate in future studies.  
Health Outcomes Data Models  
National healthcare claims data from Truven Marketscan were used in these analyses. 
This data encompasses both commercial and Medicare claims for over 65 million 
patients across the United States. Due to the limited history of ICI use in clinical practice, 
analysis of “big data” allowed us to study a large population of patients who otherwise 
would not be evaluable.  However, these data are limited to what is billed per claim for 
each patient visit. Pathology of tumors and diagnostic laboratory values, which are not 
present in the dataset, would allow for further insights into the underlying molecular 
mechanisms. Importantly, health outcomes research is understood to identify 
correlations as opposed to causation. Thus, continued validation in human peripheral 
blood samples will be important for further development as a useful clinical biomarker of 
response. 
Prospective Clinical Study Model   
We used a single site for prospective evaluation of biological markers of immune 
response from peripheral blood. There are important considerations associated with 
conclusions drawn from this clinical study. Peripheral blood samples were drawn only 
once prior to treatment limiting the analysis to a single measure of cytokine 
concentrations and immune cell populations. Also, peripheral blood concentrations of 
cytokines are notably less than within the tumor microenvironment (255, 273, 274). Of 
note, blood was drawn from a central line in NSCLC patients however was drawn by 
venipuncture in the other cohorts. Blood drawn by venipuncture may introduce 
inflammatory mediators not present from a central line blood draw. In order to reduce the 
impact of these limitations, we performed all ELISA experiments using a multiplexed kit 
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with the lowest level of detection (LLD) on the market. Although the kit allowed for levels 
of 15 different cytokines, only 6 could be ascertained above the LLD. 
 
Another experimental consideration in the prospective clinical study is the lack of PD-L1 
expression data on the tumor from prior biopsies of the included NSCLC patients. A 
comparison of the predictive ability of the peripheral immune profiles identified in this 
clinical study to the clinical assessment of PD-L1 would have aided in determining the 
value of the peripheral blood analysis. PD-L1 status is not routinely ordered for patients 
to be treated with a PD-1 or PD-L1 inhibitor in the clinic. To address this limitation, we 
assessed PD-L1 status expressed on PBMC in peripheral blood as a surrogate as it has 
been previously shown to be readily detectable from peripheral blood (275).  
 
B. CONTRIBUTION TO THE FIELD 
 
This work makes a substantial contribution to an improved understanding of immune 
checkpoint inhibition and immune response to cancer.  The rising costs of 
immunotherapy treatment are a burden for patients to bear. The identification of effective 
ways of minimizing non-beneficial medication use and maximizing outcomes would aid 
in their decision to proceed with treatment. Our work and the work of others have 
identified multiple potential peripheral blood-sampled biomarkers that could underlie 
responsiveness to ICIs (93, 94, 99, 102-104, 276). (see also Chapter 1). In a study by 
Farsaci et al, peripheral immunoscores were established from analysis of PBMC prior to 
treatment with vaccine therapy to prostate specific antigen (PSA) to define whether there 
was a correlation of what with efficacy of immune-based treatment (87).  Their approach 
similarly assessed PBMC for immune cell populations but did not assess cytokine 
concentrations from plasma. In addition, the Farsaci, et al. study did not assess a 
 114 
 
peripheral immunoscore prior to the use of ICIs. Importantly, their study was able to 
identify a peripheral immunoscore capable of predicting improvements in progression-
free survival (PFS). Martens et al explored combinations of 28 potential biomarkers 
sourced from peripheral blood prior to cytotoxic T lymphocyte antigen-4 (CTLA-4) 
inhibitor (88). A six-candidate combination biomarker was identified to be predictive of 
improve overall survival; low LDH count, elevated eosinophils, low absolute monocytes, 
high absolute lymphocytes, low Lin−CD14+HLA-DR-/low myeloid-derived suppressor cells 
(MDSC), frequencies, and elevated CD4+CD25+FoxP3+ Treg frequencies. Similarly to 
Farscai et al, this study did not evaluate cytokine concentrations. Another difference is 
the assessment of baseline markers prior to anti-CTLA-4 treatment in melanoma 
patients whereas our focus was on anti-PD-1 or anti-PD-L1 treatment in NSCLC 
patients. 
 
To our knowledge, our study is the first to identify potential biomarkers of response to ICI 
therapy utilizing health outcomes research data. Our own mining of this dataset was 
successful in identifying chronic inflammation as a precursor to durable response. I have 
shown that the analysis of national patient data can be used to inform biomarker 
characterization and drive clinical study design, limiting the expensive cost of large 
prospective adequately-powered clinical trials. This concept of using health outcomes 
data principles to drive translational research efforts remains to be rigorously tested, but 
provides a hypothesis to be further explored by those in the field.   
 
C. TRANSLATIONAL AND CLINICAL RELEVANCE 
 
The findings presented in this work are fully translatable for clinical application.  Each of 
the formulated hypotheses and aims in this work were made with particular concern for 
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their impact on patient care.  Furthermore, the approaches used bridged both basic 
science and clinical fields, thus being largely translational in nature. 
 
Improving the methods by which appropriate patients are selected for treatment with ICIs 
can properly balance cost-efficiency of this class of medications in the clinic.  The cost of 
nivolumab treatment is estimated to be greater than $100,000 per year due to the 
continuous administration schedule (277). The median PFS of 9 months or longer, 
depending on the agent used, may be worthwhile for durable responders but the cost 
may be too great for those patients that gain little to risk no benefit. The impact of failed 
treatment on health care costs, quality of life, and outcome are driving forces in the focus 
on predicting response to cancer therapies.  I have made a significant effort in 
understanding the relationship of inflammation and response to ICI therapy in a clinical 
setting, but more validation is necessary prior to implementation into practice. The 
ongoing clinical study requires completion with accrual targets for all cohorts to firmly 
assess significance of results in an appropriately powered cohort study. If our findings of 
the two combination pairs of peripheral immune data remain predictive of response, a 
prospective validation study will be conducted to affirm their utility. Translating our 
findings to a clinically useful diagnostic is difficult, but addresses the broader clinical 
needs of the health care system.  Successful implementation of the model could 
significantly impact health care costs and outcomes associated with ICI use. 
 
One common practice utilized in anti-cancer therapy is the implementation of drug 
combinations to combat resistance and to synergistically improve outcomes compared to 
each agent separately.  The probability of a tumor cell becoming resistant to a 
combination therapy of two agents with differing mechanisms of action is far less than 
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the probabilities of the development of resistance to each individual agent alone (278, 
279). If patients, at baseline, do not have the immune profile deemed as predictive as a 
response, a secondary agent could be used to “prime” the patient’s immune profile to 
become responsive to ICI therapy. Thus, identifying effective drug combinations for 
treating NSCLC is paramount.    
 
D. CONCLUSIONS 
 
I conclude that chronic inflammation can be defined by a specific immune profile 
consisting of cytokines and immune cell populations and believe that chronic 
inflammation is predictive of response to ICI in NSCLC. This profile could aide in 
identifying and stratifying NSCLC patients who will benefit from ICI therapy.  Enrichment 
of the treated population for responders will significantly impact the clinical utility of these 
agents. The research methods employed here allowed us to characterize potential 
biomarkers from peripheral blood without the cost of a large prospective clinical study. 
Furthermore, we conclude that coupling bioinformatics principles with basic science 
experimental approaches can bridge the gap of understanding of translating findings to 
clinical application. 
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